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ABSTRACT 
 
 
The incidence and prevalence of diabetes is increasing worldwide at alarming rates, making 
the disease a major health burden. Enhanced understanding of the disease aetiology is 
therefore extremely important as it would improve the treatment, and possibly the prediction 
and prevention of diabetes. Diabetes is a complex disease with two major subtypes, the 
autoimmune type 1 (T1D) and the metabolic type 2 diabetes (T2D). This diagnostic 
subdivision is, however, especially in adults, intricate, and clinical evidence even suggests an 
overlap between T1D and T2D. Autoantibodies are a hallmark of T1D but are also detectable 
in 3 to 11% of European patients diagnosed with T2D. This autoantibody-positive diabetic 
subtype is termed latent autoimmune diabetes in adults (LADA) and is considered by the 
WHO a slowly progressive form of T1D. This classification of LADA is, however, based on 
comparison with T1D diagnosed in childhood, whereas studies comparing LADA and T1D 
patients diagnosed in a similar age range are lacking. A clear genetic predisposition exists for 
both T1D diagnosed <15 years and T2D, and to date several candidate genes have been 
identified for both subtypes, contributing to increased knowledge of the biological 
mechanisms underlying diabetes. With respect to LADA and adult-onset T1D, much less is 
known about genetic predisposition. 
The aims of the study were 1) to compare LADA and adult-onset T1D patients with 
respect to clinical characteristics, prevalence and phenotypic associations of zinc transporter 
type 8 autoantibodies (ZnT8A), and associations with selected gene variants predisposing to 
T1D or T2D, 2) to investigate genetic heterogeneity in LADA related to glutamic acid 
decarboxylase autoantibody (GADA) reactivity level and family history of T1D, and 3) to 
assess the phenotypic associations of the T1D-susceptibility gene variants in LADA patients 
and in initially non-diabetic adults with emphasis on insulin secretion, prevalence of GADA, 
and progression to non-insulin dependent diabetes. 
Patients with T2D, LADA, and T1D diagnosed at >35 or at <20 years as well as non-
diabetic subjects were recruited as part of the Botnia Study or the FinnDiane Study. Diabetes 
was diagnosed based on WHO criteria. Fasting C-peptide concentration <0.2 nmol/l at the 
time of the investigation and initiation of insulin treatment within 6 months after diagnosis 
were included as criteria for diagnosis of T1D. LADA was defined as initial diagnosis of 
T2D, >35 years at diagnosis, GADA positive, and no insulin treatment in the first 6 months 
after diagnosis. Genetic susceptibility to T1D was represented by variants in HLA-DQB1, INS 
(rs689), PTPN22 (rs2476601), and CTLA4 (rs3087243), and genetic susceptibility to T2D was 
represented by variants in TCF7L2 (rs7903146), SLC30A8 (rs13266634), KCNQ1 
(rs2237895), PPARG (rs1801282), and FTO (rs9939609).  
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Variants in HLA-DQB1, PTPN22, and TCF7L2 were associated with LADA in 
general, and variants in CTLA4 and SLC30A8 were associated with LADA with high and with 
low GADA levels, respectively. Regarding the frequency of both T1D- and T2D-
susceptibility variants, LADA differed from adult-onset T1D patients. We also observed, 
immunologically, differences between LADA and adult-onset T1D patients. Hence, the 
ZnT8A were significantly more prevalent among LADA patients but associated with shorter 
disease duration only in the adult-onset T1D patients. Among the LADA patients, increased 
GADA reactivity was associated with higher frequencies of the T1D-susceptibility gene 
variants (HLA-DQB1, PTPN22, and CTLA4), lower frequency of the T2D-susceptibility gene 
variants (SLC30A8 and FTO), lower insulin secretion, and lower BMI, whereas family history 
of T1D was associated with increased frequencies of HLA-DQB1-risk genotypes and reduced 
frequencies of TCF7L2-risk genotypes.  
In non-diabetic adults followed prospectively, HLA-DQ and PTPN22 risk genotypes 
were associated with the presence of GADA. These associations were accentuated in subjects 
with a family history of T1D, and in this group even the INS-risk genotype was associated 
with GADA. Furthermore, non-diabetic adults with a higher number of T1D-susceptibility 
genotypes (HLA-DQ, PTPN22, INS, and CTLA4) were unable to increase the insulin secretion 
to a level similar to those with a lower number of risk genotypes in response to the reduced 
insulin sensitivity at follow-up. However, the T1D-susceptibility genotypes were not 
associated with progression to non-insulin-dependent diabetes in these initially non-diabetic 
adults. In LADA patients, both an increased number of T1D-susceptibility genotypes and the 
T2D-associated SLC30A8 R325W variant were associated with reduced insulin secretion. 
With respect to the T1D-susceptibility genotypes, the same tendency was observed among 
T2D patients. 
In conclusion, LADA shared a genetic predisposition with both T1D and T2D. And 
both family history of T1D and level of GADA reactivity contributed to heterogeneity in 
LADA. Comparison of LADA and adult-onset T1D patients revealed genetic, phenotypic, and 
immunological differences. Our data suggest that LADA, rather than an age-related extension 
of T1D, is a slowly progressive form of autoimmune diabetes distinct from T1D. 
Furthermore, T1D-susceptibility gene variants signify a mild beta-cell destruction in non-
diabetic adults as well as in LADA and T2D patients.  
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REVIEW OF THE LITERATURE 
 
 
The prevalence of diabetes has reached epidemic proportions, making this disease a huge 
health burden on society in both developed and developing countries [1]. Worldwide, 285 
million people were estimated to have diabetes in 2010, corresponding to a prevalence of 
6.4%. By 2030, it is estimated that the number affected will rise to 439 million, equal to 7.7% 
of the world’s adult population [2]. Its extreme increase in prevalence and incidence over the 
last decades is explained primarily by changes in lifestyle and environmental exposures. 
Diabetes results from disruption of the glucose homeostasis. The disease can cause 
micro-vascular complications such as retinopathy, nephropathy, and neuropathy, macro-
vascular complications such as coronary heart disease, cerebrovascular disease, and peripheral 
vascular disease, and ultimately death if left untreated. On the molecular level, the specific 
cause of diabetes is poorly understood. Improved understanding of the aetiology of diabetes is 
of great importance, as it would improve treatment and prevention possibilities.  
 
1. DIABETIC SUBTYPES 
Diabetes is a complex and heterogeneous disease with a number of subtypes. These include 
T1D, T2D, LADA, maturity onset diabetes of the young, gestational diabetes, neonatal 
diabetes, and maternally inherited diabetes and deafness [3-6]. The biological mechanisms 
underlying the development of diabetes include reduced insulin secretion, and increased 
insulin resistance in skeletal muscles, adipose tissue, and in the liver. These two mechanisms 
contribute to a varying degree to the pathogenesis of the different diabetic subtypes. 
 
1.1. Type 1 diabetes 
Among all cases of diabetes in Finland, T1D accounts for approximately 15%. The disease 
incidence varies about 100-fold across the world. Finland has the highest incidence, with >50 
per 100 000 in <15-year-olds, whereas the rate in Venezuela and China is only 0.1 to 4.5 per 
100 000 [7, 8]. This geographical incidence variability is thought to be a result of differing 
genetic backgrounds and environmental exposures. The changing environment also may be 
the underlying reason for the increasing incidence rate observed over the last three decades 
worldwide [7-9]. This is illustrated by the reduced frequency of newly diagnosed children 
with high-risk HLA genotypes, despite an unchanged frequency of these genotypes in the 
general population, indicating that the environmental pressure has increased and predisposes 
less genetically susceptible individuals to disease [8, 10]. 
In most cases, T1D is caused by autoimmune destruction of the insulin-producing beta-
cells in the pancreas, which is mediated by infiltrating T-cells. Figure 1 depicts the most 
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recognized model of T1D development. This process is initiated by the interaction between 
susceptibility genes and environmental predisposing factors, and this triggers the autoimmune 
reaction. The first molecular markers of this process are autoantibodies directed towards 
insulin (IAA), followed by autoantibodies towards islet cells (ICA), glutamic acid 
decarboxylase (GADA), tyrosine phosphatase-like IA-2 protein (IA-2A), and zinc-transporter 
type 8 (ZnT8A) [11-13]. These autoantibodies are apparent in the early stages of the disease 
process. In this process, destruction of the beta-cells initially leads to loss of the first-phase 
insulin response. A second wave of environmental exposure is thought to trigger additional 
changes in the T-cell phenotype and to tip the Th1-Th2 balance, which intensifies the 
autoimmune attack. When about 80% of the beta-cells are destroyed, insulin secretion is 
insufficient to maintain glucose homeostasis; then overt diabetes occurs [14, 15].  
 
 
 
 
Figure 1 Model of the pathogenesis of T1D. Adapted by permission from BMJ Publishing Group 
Limited. Devendra et al., 2004 [15]. 
 
 
T1D is usually considered a disease with its onset in childhood, yet about 30% of T1D 
patients are diagnosed after the age of 30 [16-19]. Compared with T1D children, adult-onset 
patients usually display less severe symptoms at presentation [20, 21]. In these adult-onset 
patients, GADA is the most prevalent autoantibody, whereas the decrease in ICA, IA-2A, 
IAA, and ZnT8A prevalence is more apparent with both increasing age at onset and disease 
duration [21-26].  
In first-degree relatives as well as in the general population, autoantibodies have a high 
predictive value for T1D. Multiple antibody-positivity is associated with an >65% risk for 
developing T1D within 5 to 15 years [27-29], whereas single antibody-positivity implies only 
a small risk, ranging from 3.4 to 4.0% for GADA, ICA, and IAA [30]. Whether 
autoantibodies also are directly involved in the pathogenesis of T1D is unknown. Compelling 
evidence exists of the involvement of environmental factors in the pathogenesis of T1D, but 
despite extensive research, no environmental triggers have conclusively been identified. Thus 
far, the strongest evidence is for dietary proteins from cow’s milk [31, 32] and for early 
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childhood infections, supported by a possible north-south gradient [8] and seasonality of 
disease incidence [33, 34]. However, vitamin D exposure, obesity, and environmental 
pollutants, especially from pesticides, have also been extensively studied but with very 
conflicting results [9]. 
 
1.2. Type 2 diabetes 
T2D is estimated to account for 80 to 90% of all cases of diabetes. The prevalence of diabetes 
among individuals 20 to 79 years of age ranges worldwide from 3.8% in Africa to 8.1% in 
Europe and 11.7% in North America [35]. The worldwide prevalence of T2D has increased 
dramatically over the last 30 years, most likely as a consequence of the increased proportion 
of elderly people and the increased prevalence of obesity. 
Even though T2D is far more prevalent than T1D, the aetiology of this diabetic subtype 
is less-well understood. Its pathogenesis can involve variable degrees of increased insulin 
resistance and reduced insulin secretion. Whether the disease-causing reduction in insulin 
secretion is attributable to reduced beta-cell mass or to reduced beta-cell function is, however, 
unclear [36]. Insulin resistance is a state in which the effect of insulin, the key regulator of 
blood glucose level, is reduced in target tissues. The main target tissues are skeletal muscles, 
where insulin induces glucose uptake; the liver, where insulin suppresses the endogenous 
glucose production; and adipose tissue, where insulin suppresses lipolysis. Because adipose 
tissue secretes signalling molecules including hormones, cytokines, and free fatty acids, all of 
which modulate insulin action, insulin resistance is strongly associated with obesity. Age is 
another factor strongly associated with increasing insulin resistance.  
 
 
 
 
Figure 2 Natural history of T2D. The roles of insulin resistance and of insulin deficiency are 
highlighted. Adapted from Kendall et al., 2005 [37] with permission from Elsevier. 
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Figure 2 depicts T2D development in terms of insulin resistance and insulin secretion. 
Beta-cells adjust insulin production to the state of insulin resistance in order to maintain 
normo-glycaemia. Development of T2D is a progressive process, in which hyperglycaemia is 
observed at an early stage as a consequence of insulin resistance or impaired insulin secretion 
or both. Persistent hyperglycaemia contributes to progressively increasing insulin resistance 
forcing the beta-cells to compensate by secreting additional insulin. At some point, the beta-
cells fail to compensate, and diabetes ensues (Figure 2). The beta-cell potential is individual, 
and is associated with risk factors for development of T2D, mainly genetic predisposition, 
family history of diabetes, lifestyle, and intra-uterine environment [38-41]. 
 
1.3. The grey zone between type 1 and type 2 diabetes  
In clinical practice, diabetes is often classified as T1D or T2D based on phenotypic 
characteristics including acuteness and age at onset, occurrence of ketoacidosis, need for 
insulin treatment, and body weight and composition, as well as existence of autoimmune 
diseases. The classification is, however, not always straightforward. Especially in young and 
middle-aged adults the difference between T1D and T2D is not clear-cut, and clinical 
evidence even supports an overlap between T1D and T2D. The two diabetic subtypes cluster 
in the same families [42]. Family history of T2D is associated with a higher prevalence of 
T1D compared with prevalence in the general population [43-47], plus later onset, increased 
prevalence of the metabolic syndrome, increased BMI, and factors related to insulin resistance 
in T1D patients [48, 49]. Similarly, family history of T1D is associated with increased 
frequency of T2D [50, 51], and among T2D patients with reduced BMI and C-peptide level, 
as well as higher prevalence of GADA positivity [52, 53]. Moreover, in initially non-diabetic 
adults, family history of T1D and GADA are associated with development of non-insulin-
dependent diabetes [54]. This familial clustering may indicate that T1D and T2D share 
disease-underlying genetic and environmental factors. 
 
1.4. Latent Autoimmune Diabetes in Adults - LADA 
LADA is a diabetic subtype in the grey zone between T1D and T2D. Among patients of 
European ancestry initially diagnosed with T2D, LADA accounts for 3 to 11% [55-59]. Its 
prevalence varies according to population origin, ascertainment, and the diagnostic criteria 
applied for LADA. LADA diagnosis is based on age at onset, time between diagnosis and 
initiation of insulin treatment, and presence of autoantibodies [4], of which GADA is the most 
common type among these patients [60]. Each of these criteria is based on an arbitrary cut-off 
value, making the diagnosis of LADA unspecific and variable between studies. Table 1 shows 
the differences in diagnostic characteristics for T1D, LADA, and T2D patients. 
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Table 1 Diagnostic characteristics of diabetes in adults 
 T1D LADA T2D 
Metabolic syndrome + ++ +++ 
Ketoacidosis + +/- - 
Complications + + + 
Autoantibodies Positive/negative Positive (required) Negative (required) 
Age at diagnosis Usually childhood* Usually >35 Usually >40 
Insulin treatment At diagnosis Not at diagnosis  +/- 
*About 30% are diagnosed at >30 years. 
 
In the few existing prospective studies on LADA patients, about 50% required insulin 
after 6 to 10 years of follow-up [55, 61]. However, the clinical phenotype of LADA patients 
is highly affected by their level of GADA positivity. A high GADA level is associated with 
reduced beta-cell function, with lower BMI, with lower prevalence of markers of the 
metabolic syndrome, and possibly with lower age at diagnosis, as well as with an increased 
insulin requirement [56, 62-65]. In a small study, a high GADA level has further been 
associated with a higher prevalence of ketosis and diabetic complications [66].  
Clinically, LADA appears to be intermediate between T1D and T2D. This notion is 
based on measures of BMI, lipids, presence of the metabolic syndrome, blood pressure, and 
prevalence of hypertension [56, 59, 62, 67-72]. Insulin resistance is more pronounced in 
LADA patients than in T1D patients, whereas it is controversial whether insulin resistance in 
LADA patients is lower than in T2D patients [56, 67, 73, 74] or similar [69, 75, 76]. This 
discrepancy may be due to differences in age and BMI between LADA and T2D patients 
included in the different studies, as both these factors are strongly correlated with insulin 
resistance. Moreover, in LADA patients compared with T1D patients, the insulin requirement 
is reduced, and serum C-peptide concentrations are higher [56, 70, 71] and decline at a slower 
rate, according to some [77], but not all studies [71]. The opposite is observable in 
comparison of LADA with T2D [55, 56, 77, 78]. LADA patients are therefore considered 
more insulin deficient than are T2D patients. Risk factors for developing LADA, identified in 
population-based prospective or cross-sectional studies, are similar to those of T2D and 
include increased age, over-weight, family history of diabetes, increased waist-hip ratio, 
stress, and physical inactivity [79-81].  
It is evident that diabetes, and in particular LADA, is a heterogeneous disease. This 
heterogeneity is a reflection of the complex interplay between genes and environment. 
Improved understanding of factors underlying the disease is the key to improving treatment 
and potentially preventing diabetes. 
 
2. GENETICS OF DIABETES 
An important step in the quest towards understanding mechanisms underlying development of 
diabetes is to identify the disease-predisposing gene variants, as it is clear that not all 
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individuals are equally susceptible to the diabetogenic environment of our modern society. 
Identification of these gene variants can elucidate pathways involved in diabetes pathogenesis 
and possibly contribute to identification of individuals at increased risk for developing the 
disease. The range of both effect size and prevalence of variants underlying common diseases 
is largely unknown and therefore so is the expected number of disease-predisposing variants 
[82].  
Evidence of a genetic component in the pathogenesis of diabetes comes from twin, 
family, adoption, and admixture studies. Having parents with diabetes imposes an increased 
risk for diabetes. If the mother has T1D, the child’s lifetime risk for T1D is 1 to 3%, and if the 
father is affected the risk is 4 to 9% [83] compared with only about a 0.4% prevalence in the 
general population. Having one parent with T2D imposes a lifetime risk of developing T2D of 
40%, and if both parents are affected, the lifetime risk is 70%, compared with 10% for the 
general population [84, 85]. The genetic contribution is also evident from twin studies, where 
the concordance rate is higher in mono- than in dizygotic twins. For T2D, the concordance 
rate in monozygotic twins is 35 to 80%, whereas it is 15 to 35% in dizygotic twins [86-90]. 
For T1D, these rates are 20 to 50% and 5 to 10%. The fact that the concordance rates among 
monozygotic twins are less than 100% for both T1D and T2D points to an environmental 
component in disease aetiology as well. Among monozygotic twins discordant for T1D, the 
risk for T1D developing in the non-affected twin depends on age at diagnosis in the affected 
twin, with the risk being 38% if the affected twin developed T1D <24 years old, and only 6% 
if T1D developed >25 years [91]. This variation in risk may indicate a stronger genetic 
component in early- vs. late-onset T1D.  
 
2.1. The hunt for diabetes susceptibility genes – the pre-GWAS era 
Until about five years ago, the genetics of common complex diseases was investigated by 
linkage analysis or in case-control studies by applying the candidate-gene approach. In 
linkage analysis, a disease-causing locus is mapped by identifying co-segregation between 
polymorphic genetic markers and disease in families with multiple affected members [92]. 
This method has been very successful in detecting rare variants with high penetrance 
underlying monogenic Mendelian disorders (Figure 3) [93]. But for common complex 
diseases like T1D and T2D, the success of the linkage approach has been very limited [94]. 
This lack of success is mostly due to the low penetrance of the risk alleles. A linkage study 
with enough statistical power to identify a risk locus with an effect size similar to that of 
known T2D variants would require an extremely large number of families, thus making it 
impossible to perform. Another problem with linkage studies is their low mapping resolution, 
making the identification of the causal variant underlying the linkage signal difficult [95-99].  
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Figure 3 Detectability of disease susceptibility variants depending on effect size and frequency of 
the risk allele. The diagonal dotted lines mark the focus area of genetic studies. Adapted by 
permission from Macmillan Publishers Ltd: Nature [100], copyright (2009).   
 
 
Contrary to the linkage approach, a candidate-gene study relies on an a priori 
hypothesis of involvement of the gene in the disease pathogenesis. The candidate genes can 
be chosen based on knowledge of biological function from genetically engineered animal 
models or cell studies, based on involvement in monogenic forms of the disease, or based on 
knowledge of drug targets for the disease [101, 102]. Like linkage analysis, the success of the 
candidate-gene approach in identifying gene variants underlying common complex diseases 
has been limited [103]. Reasons for this lack of success include the facts that 1) knowledge of 
the biological mechanisms underlying most complex diseases, crucial for selection of the 
candidate gene, is sparse, 2) the case-control study design is vulnerable to population 
stratification, leading to false positive associations impossible to replicate, and 3) many 
studies have suffered from small sample size and insufficient phenotyping, reducing 
penetrance [102, 104]. Sample size is crucial, given that the effect size of common variants 
associated with common diseases seems to be extremely modest. Hence, a study with a small 
sample size is limited by its statistical power. With an effect size of 1.3 (odds ratio, OR) and a 
minor allele frequency <10%, more than 10 000 cases and 10 000 controls are required to 
obtain a power of 80% to find an association with a convincing p-value [105]. One way to 
overcome the sample-size problem is to combine studies in a meta-analysis [106]. This study 
design, however, comes with its own set of potential problems, including publication bias and 
heterogeneity between study populations [107]. 
 
2.2. The hunt for diabetes susceptibility genes – the GWAS era 
The advent of genome-wide association studies (GWAS) was a major breakthrough in 
identification of gene variants underlying complex diseases. This breakthrough was facilitated 
by advances within several areas. Firstly, the HapMap project [108-110], and later the 1000 
Genomes Project [111] contributed with the characterization of single nucleotide 
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polymorphisms (SNPs), haplotype structure, and linkage disequilibrium (LD) patterns across 
the genome. LD refers to non-random correlation between alleles at different loci and 
theoretically allows identification of association with a proxy for the true causal variant 
without impeding statistical power [112-114]. In practise, this means that it is sufficient to 
type about 500 000 carefully selected tagSNPs to gain information about the approximately 
10 million common variants in the human genome [115, 116]. Secondly, the GWAS were 
facilitated by development of commercially available, automated, and affordable genotyping 
technology and advances in statistical methods, as well as collection of sufficiently large 
sample sets through international collaboration [103].  
The contribution of GWAS to knowledge on genetics of common complex diseases is 
enormous. But despite the large number of susceptibility variants identified for T1D and T2D, 
genetic prediction of disease development is still poor [117, 118]. Because the GWAS are 
independent of prior biological knowledge, those susceptibility genes identified have pointed 
to new T1D- and T2D-associated biological pathways [119, 120]. Biological knowledge will 
potentially further increase when the causal variants for the remainder of the statistical 
associations are identified. Genetic information can also prove relevant in motivating patients 
to change their lifestyle, in identification of possible new drug targets, and in choice of 
intervention or treatment [121, 122].  
The major drawback in GWAS design is the limitation in what is detectable, as depicted 
in Figure 3. The SNPs on the GWAS genotyping arrays are chosen to be common, with minor 
allele frequencies >5%. Hence, GWAS are by design only powered to detect association with 
variants that are common in the population, because the strength of a statistical association 
between two markers depends on the LD between them. If allele frequencies of the markers 
differ considerably, the LD between them is low and so is the strength of the association 
[123]. The common variants identified only explain a fraction of the common disease 
heritability [100, 117, 124].  Researchers have therefore speculated where to find the 
remainder of the genetic variation and what methods to apply to find it [100]. Currently, 
whole-genome and exome sequencing is performed to identify low-frequency variants 
associated with disease. This type of variation may prove to be of particular importance, 
because natural selection will maintain deleterious variants at low frequency. This notion is 
supported by HapMap data showing that rare variants are more likely to be disease-
predisposing than are common variants [125]. It is, however, also possible that other types of 
variation and mechanisms contribute to the heritability of common diseases; these include 
copy-number variants and gene-gene and gene-environment interactions, as well as epigenetic 
variability. Thus far, it seems unlikely that copy-number variants will explain additional 
variation involved in the pathogenesis of either T1D or T2D, as this type of variation is well 
tagged by SNPs on current GWAS arrays [126]. On the contrary, the contribution of 
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epigenetics is very plausible and could provide the link between genetic and environmental 
predisposition.  
 
2.3. Genetics of type 1 diabetes 
Currently more than 50 susceptibility loci have been robustly associated with T1D [127]. 
Knowledge of the genetic predisposition to T1D is primarily based on studies of classical 
T1D patients diagnosed in childhood or early adulthood, whereas studies of adult-onset T1D 
are lacking.  
Figure 4 displays T1D-susceptibility loci identified up to the year 2009 [128-139]. The 
candidate-gene approach contributed only five loci identified between 1970 and 2005. 
Thereafter, the risk loci have been identified by GWAS, or by meta-analyses of GWAS 
datasets. It is evident from Figure 4 that effect sizes are decreasing as time progresses, 
attributable to the greater sample size in the most recent studies.  
 
 
 
Figure 4 Non-HLA T1D-associated loci identified in candidate-gene studies (light-blue) or GWAS 
(dark-blue). The loci are represented by the assumed causal gene. Adapted from Todd 2010 [120] 
with permission from Elsevier.  
 
 
Estimates are that the identified variants combined explain about 75% of the heritability 
of T1D [117]. Some of the associated loci lack any compelling functional candidate gene 
(Figure 4). For others, the strong causal candidate genes identified point to pathways involved 
in the aetiology of T1D. Among the genes with strong functional support for their 
involvement in the pathogenesis of T1D are the human leukocyte antigen (HLA) on 
chromosome 6p21.3, protein tyrosine phosphatase, non-receptor type 22 (PTPN22) on 
chromosome 1p13, insulin (INS) on chromosome 11p15, and cytotoxic T-lymphocyte-
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associated antigen (CTLA4) on chromosome 2q33. These loci are described in the following 
with key data summarised in Table 2. 
 
The HLA region 
The association between HLA alleles and T1D was reported in candidate-gene studies back in 
the early 1970s [128, 140, 141], and has subsequently been replicated in numerous studies - 
candidate-gene as well as GWAS - comprising differing ethnic populations [133, 136, 139, 
142-144]. With an OR of at least 6, HLA is the major susceptibility locus in T1D and 
accounts for approximately 40% of its heritability [145].  
 
 
 
Figure 5 Genes in the HLA region and main T1D-risk and –protective haplotypes.  
 
 
The HLA region is characterised by a high degree of LD, which complicates assessment 
of specific disease-associated loci. Figure 5 depicts the three gene subclasses in the HLA 
region. The primary T1D-risk association is attributed to the HLA-DQ genes and modified by 
the HLA-DR genes, but association is also indicated for the HLA class I genes, namely HLA-
A and HLA-B [142, 143, 146]. In Finland, the DQB1*0302 allele on the DR4 haplotype is 
associated with the highest risk for T1D, especially when it is co-expressed with the 
DQB1*0201 allele on the DR3 haplotype [146, 147]. Prevalence of risk-associated alleles 
varies across Europe. In Finnish T1D children, either or both of these alleles are found in 
about 90%, compared with their presence in about 40% of Finnish newborns [146, 147]. The 
DQB1*0602(3) allele on the DR2 haplotype is associated with dominant protection against 
T1D, and is found in about 36% of Finnish newborns compared with in about 3% of Finnish 
T1D children [146, 147]. In studies of patients mainly <40 years, prevalence of the high-risk 
genotypes DQB1*02/*0302 and *0302 (or corresponding DR genotypes), is negatively 
associated with age at diagnosis of T1D, whereas the protective DQB1*0602 genotype has 
been positively associated with age at diagnosis [20, 21, 148-154]. Recently, these findings 
were extended to patients >44 years with autoimmune diabetes [155]. 
A clear functional link exists between variation in HLA genes and T1D. HLA proteins 
bind foreign- and self-derived antigens and present them to CD4- and CD8-positive T cells, 
which activates the immune system and controls T-cell selection [156]. The affinity and 
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stability of this antigen binding is influenced by variation in DQB1; it is hypothesized that 
susceptibility alleles bind pancreatic antigens less efficiently, which reduces the deleterious 
signal in autoreactive T-cells, enabling them to escape from negative selection in the thymus 
[157, 158]. 
 
The PTPN22 gene 
In 2004, an association between the PTPN22 C1858T variant and childhood T1D was 
reported in a candidate-gene study [129]. This association has subsequently been confirmed in 
GWAS and recently in large meta-analyses comprising up to 16 240 cases and 17 997 control 
subjects [134, 136, 139, 144, 159]. This association has also been observable in older patients 
with autoimmune diabetes diagnosed >17 years [155], and in Finnish T1D patients with age at 
diagnosis between 15 and 40 years [154]. The association between T1D and PTPN22 has 
been reported to be stronger in subjects with low-risk HLA genotypes [160, 161] and in 
GADA-positive T1D patients compared with GADA-negative patients [162]. 
In 546 Finnish children with T1D (mean age at diagnosis, 8.2±4.1 years) the T-allele of 
the C1858T variant was observed in 23.9%, whereas its frequency in 538 healthy infants was 
13.9% [160]. The frequency both in Finnish cases and control subjects is higher than the 
frequency observed in other populations [163, 164]. Whether the PTPN22 variant is 
associated with age at onset of T1D is controversial. In German T1D children, the T1D-
associated T-allele is associated with younger age at onset [165], but no such association 
appeared in a large UK family-based series [166], in UK T1D children <16 years [161], or in 
Finnish T1D patients of an age at diagnosis between 15 and 40 years [154].  
PTPN22 encodes the lymphoid tyrosine phosphatase (LYP), which functions as a 
negative regulator of T-cell activation by dephosphorylating T-cell-receptor signalling 
molecules [167, 168]. The C1858T variant is non-synonymous, changing arginine to 
tryptophan at position 620 (R620W), and thereby possibly changing the binding properties of 
LYP. The mechanistic link to T1D is controversial. One suggestion is, however, that the 
amino acid substitution results in gain of function [169]. Hence, in carriers of tryptophan-
containing LYP, inhibition of T-cell receptor signalling rises. In the thymus, this altered 
signalling can lead to escape of autoreactive T-cells from negative selection and thereby to 
susceptibility to autoimmune disease [164, 169].  
 
The INS gene 
The INS locus encoding the insulin protein is an obvious T1D-candidate gene, and association 
with T1D has been established in children by candidate-gene studies as well as by GWAS 
[130, 136, 170]. Similarly to PTPN22, the association between INS and T1D has been 
reportedly strongest in individuals with low-risk HLA genotypes [171, 172].  
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The INS locus accounts for approximately 10% of the heritability [145]. A high degree 
of LD characterises the INS gene region. Hence, both two SNPs, -23HphI and +1140A/C, and 
a variable number of tandem repeats (VNTR) located in the INS promoter region have been 
suggested as the causal variant underlying the association with T1D [130, 173]. Expression 
data have showed that the VNTR is associated with altered insulin transcription [174, 175]. 
Compared with the class III VNTR (141-209 repeats), the class I VNTR (26-63 repeats) is 
associated with increased INS transcription in the pancreas and decreased transcription in the 
thymus. This modulated INS expression may alter T-cell selection in the thymus and when 
autoreactive T-cells escape to the periphery reduce tolerance towards insulin [174, 175]. This 
is a possible functional link between the class I VNTR and predisposition for T1D and is 
supported by studies showing that insulin is the major initiating antigen in T1D [12, 176]. 
Interestingly, the association between INS and T1D may be modified by epigenetic CpG 
methylation in the promoter region and may depend on parental origin of the risk allele [177, 
178]. In most association studies, the -23HphI SNP is genotyped as a proxy for the VNTR, as 
the two markers are in near-perfect LD [170]. 
In Finnish T1D patients diagnosed <35 years, frequency of the T1D susceptibility 
VNTR class-I allele was 89.2%, whereas the frequency among age- and sex-matched control 
subjects was 79.5% [179]. This risk-allele frequency among Finns is higher than the 
frequency in other European subjects [136]. The INS variant has also been associated with 
T1D diagnosed in young Finnish adults (15 to 40 years at diagnosis) [154], and with 
autoimmune diabetes in German adults (>17 years at diagnosis) [155]. It is controversial 
whether the variant is associated with age at onset of T1D. In a large family-based series of 
T1D children, the INS variant was associated with older age at onset [166], but with no 
association evident in analyses of patients diagnosed at over age 15 [154].      
 
The CTLA4 gene 
CTLA4 is another T1D susceptibility locus identified in a candidate-gene study in children 
[131], and subsequently confirmed in GWAS and a meta-analysis comprising up to almost   
10 000 cases and 17 000 control subjects [136, 137, 139, 144]. As for the majority of the T1D 
susceptibility loci, the causal variant underlying the association is yet to be identified; in the 
CTLA4 region, the variants most studied are the +49 A/G and the CT60 A/G [180]. For the 
CT60 variant, an association has also been observable in adults with autoimmune diabetes 
[155], but no association was observable in Finnish T1D patients diagnosed between ages 15 
and 40  [154]. The lack of association in the latter study is possibly due to inadequate sample 
size, given the small effect size of the CTLA4 variant (Figure 4). The same study observed no 
association with age at onset of T1D [154]. Among Finnish T1D children (mean age at 
diagnosis, 9.8±3.4 years), the T1D-associated G-allele of the CTLA4 CT60 variant was 
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evident in 70.4%, whereas the frequency among non-diabetic control subjects was 66.6% 
[180]. Compared with other Europeans [136, 137], this T1D-susceptibility variant, too, seems 
to be more common among Finns.  
The CTLA4 protein is located on the surface of activated T-cells that produce negative 
signals for T-cell activation. Functional data suggest that in healthy control subjects, the level 
of soluble CTLA4 mRNA is significantly correlated with the genotype of the CTLA4 CT60 
variant, possibly explaining the association between that variant and T1D [181]. 
 
Table 2 Genetics of T1D – selected variants 
   Finnish RAF Factors affecting association 
Locus SNP Variant Controls T1D patients 
Age at 
diagnosis Other 
HLA-DQB1 Multiple 
*02/*0302 
*02 
*0302 
3% 
21% 
18% 
30% 
21% 
42% 
++ 
  
PTPN22 rs2476601 
Non-
synonymous 
R620W 
14% 24% +/- 
HLA genotype 
GADA 
positivity 
INS rs689 Non-coding -23HphI 80% 89% +/- HLA genotype 
CTLA4 rs3087243 Non-coding CT60 67% 70% -  
RAF, risk allele frequency. 
 
2.4. Genetics of autoantibodies 
The gene variants associated with T1D have also been investigated in relation to the 
prevalence of autoantibodies. In primarily T1D children, HLA-DQB1*0302 (DR4) is 
positively correlated with IA-2A, IAA, and ICA [23, 30, 155, 182-186], whereas DQB1*02 
(DR3) is negatively correlated with IA-2A [23, 155, 184, 186]. The association between HLA 
genotypes and GADA differs according to diabetes status and age at onset of T1D. In T1D 
children, GADA is associated with DQB1*02 [23, 30, 187], whereas an association with 
DQB1*02/*0302 or DQB1*0302 occurs in healthy children [188-190], and in young adults 
with autoimmune diabetes [155] or with T1D [187, 188].  
PTPN22 has been associated with GADA in T1D patients with long disease duration 
[191] and with IAA in T1D children with HLA-risk genotypes [160]. In contrast, no 
association between PTPN22 and IA-2A, GADA, or IAA was observable among 243 German 
paediatric T1D patients [186]. INS has been associated with IAA [23, 192, 193], whereas 
CTLA4 does not seem to be associated with T1D-associated autoantibodies [192, 194]. 
Recently, the genetics of islet autoantibodies (GADA, IA-2A, and ZnT8A) was 
investigated in GWAS employing >2 200 childhood-onset T1D cases. For GADA, the GWAS 
supported the primary association with HLA-DR3 (corresponding to HLA-DQB1*02), and 
further showed an association with an independent SNP in the HLA class I region, IL2RA on 
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chromosome 10p15, and SH2B3 on chromosome 12q24 [195, 196]. IA-2A was most strongly 
associated with HLA-DRB1, FCRL3 on chromosome 1q23, IL27 on chromosome 16p11, 
IFIH1 on chromosome 2q24; and further was negatively associated with HLA-A*24 [195, 
196]. ZnT8A was associated with FCRL3 on chromosome 1q23, and the HLA class I region 
[197]. In the GWAS, no association was observable between GADA, ZnT8A, or IA-2A and 
the majority of verified T1D-associated loci including PTPN22, INS, and CTLA4, as well as 
the HLA-DR3/DR4 (*02/*0302) and HLA-DR4 (*0302) genotypes. Hence, based on these 
data, the genetic predisposition for autoantibodies and T1D seems to differ [195-197]. 
 
2.5. Genetics of type 2 diabetes 
Currently more than 50 T2D-susceptibility loci are verified in Caucasians [82]. Figure 6 
displays the loci identified in candidate-gene studies (n=2) [198, 199], in large-scale 
association studies (n=3) [200-202], in the first round of GWAS with T2D as the phenotype 
[133, 203-209], and in a GWAS meta-analysis with a discovery sample comprising 4 549 
T2D patients and 5 579 control subjects of European descent (n=13) [210]. The remainder of 
the validated T2D-risk loci have initially been identified in an even larger meta-analysis [124, 
211] and in GWAS of intermediate phenotypes, such as fasting and 2-hour glucose and 
fasting insulin and proinsulin, as well as measures of insulin resistance and insulin secretion 
in healthy individuals [212-220].  
 
 
 
 
Figure 6 T2D-associated loci identified in candidate-gene studies (light-blue), large-scale 
association studies (medium-blue), or GWAS (dark-blue). The loci are represented by the assumed 
causal gene. Adapted from Prokopenko et al. [221] with permission from Elsevier. 
 
 
It is evident from Figure 6 that the effect sizes of the T2D-risk variants are small. 
However, the overlap between T2D-susceptibility loci in Caucasian and Asian populations is 
extensive, suggesting that these associations are explained by causal variants with low effect 
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sizes in high LD with the identified tagSNPs, rather than causal variants with large effect 
sizes in low LD with the tagSNP [82, 222]. 
The annotated T2D-susceptibility genes are inferred from the associated SNPs, of which 
the majority are located in non-coding regions. Hence, the annotation is tentative, and for 
most of the loci the causal variant and thereby the direct functional link to T2D is unknown. It 
is, however, evident that most of the T2D-associated genes identified are involved in beta-cell 
development, function, or beta-cell mass regulation, including transcription factor 7, like 2 
(TCF7L2) on chromosome 10q25; solute carrier family 30, member 8 (SLC30A8) on 
chromosome 8q24; and the potassium voltage-gated channel, subfamily Q, member 1 
(KCNQ1) on chromosome 11p15. Few genes that are involved in insulin resistance have been 
identified, including peroxisome proliferator-activated receptor γ (PPARG) on chromosome 
3p25, and fat mass and obesity associated (FTO) on chromosome 16q12 [221,223, 224]. 
These loci are described in the following with key data summarised in Table 3. 
 
The TCF7L2 gene 
Based on a linkage study suggesting association with T2D on chromosome 10q [225], a large-
scale association study of micro-satellites identified the TCF7L2 rs7903146 variant [200]. 
This intronic variant is thus far the strongest genetic risk factor for T2D, with an OR >1.3, and 
its association with T2D has been replicated in numerous studies and in different ethnic 
populations [226, 227]. In non-diabetic Finnish subjects, the frequency of the T2D-associated 
rs7903146 T-allele has been reported to be 18% [206, 228], lower than the frequency 
observed in other European subjects [229].  
In population-based samples and in healthy subjects, the rs7903146 T-allele has been 
associated with an increased pro-insulin-to-insulin ratio, with reduced insulin secretion, with 
an enhanced rate of hepatic glucose production, and with impaired incretin effects [228, 230-
233]. The exact mechanistic link between the TCF7L2 variant and reduced beta-cell function 
is, however, still unclear. The TCF7L2 protein product is a transcription factor involved in the 
WNT-signalling pathway. In islets from T2D patients carrying the T2D-associated T-allele of 
the rs7903146 variant, TCF7L2 transcription is increased [230]. And overexpression of 
TCF7L2 in human islets has been associated with reduced glucose-stimulated insulin 
secretion [124, 230]. The T-allele has also been associated with a more open chromatin state 
in human islets and with greater enhancer activity [234]. The chromatin state may signify 
increased transcription of TCF7L2. Together, these studies provide a possible functional link 
for the intronic variant.  
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The SLC30A8 gene 
The SLC30A8 R325W variant was identified as a T2D-susceptibility variant in the first 
published T2D GWAS [203], and has been confirmed in subsequent studies [235]. In Finnish 
non-diabetic subjects, the frequency of the T2D-associated C-allele was 61% [206, 228], 
which is lower than the frequency observed in non-diabetic UK subjects [205].   
In normal glucose-tolerant subjects, the T2D-associated C-allele of the R325W variant 
is associated with traits related to beta-cell function, ones such as conversion of pro-insulin to 
insulin [219, 236], reduced insulin release, and first-phase insulin response [124, 204, 228, 
237, 238]. Even though no effect of the variant was observable on basal or stimulated insulin 
secretion in human islets in vitro [235], R325W is most likely the causal variant, and strong 
evidence exists for the underlying mechanism. SLC30A8 encodes the zinc transporter type 8 
(ZnT8); this protein is islet-specific and facilitates proper storage and secretion of insulin 
[239], and it is an example of a possible new drug target identified based on genetic 
information [240]. Drug-mediated enhancement of the intracellular function of the zinc 
transporter could potentially improve insulin secretion. Its potential as drug target is 
supported by studies showing that ZnT8 downregulation in INS-1 cells reduces glucose-
stimulated insulin secretion, whereas ZnT8 overexpression had the opposite effect [239, 241]. 
ZnT8 also provides an interesting link between T2D and T1D, because the protein is the 
target of the ZnT8 autoantibodies, and the R325W variant determines antigen specificity in 
T1D patients but is not associated with T1D [242, 243]. 
 
The KCNQ1 gene 
Two independent Japanese GWAS identified KCNQ1 as a T2D-susceptibility gene, an 
association subsequently replicated in Europeans [124, 208, 209]. This association was 
missed in the first round of European GWAS, illustrating the importance of considering 
differing ethnic groups when mapping genetic associations. In population-based Finnish 
samples, the T2D-associated C-allele of the KCNQ1 rs2237895 variant was observable in 47 
to 49% [244]. This is higher than the frequency observed in Danish subjects with normal 
glucose tolerance [208]. KCNQ1 encodes the pore-forming alpha subunit of the IKsK+ channel 
expressed in the pancreas [208, 209], making it a good T2D candidate gene. Following an oral 
or intravenous glucose load in glucose-tolerant individuals, the T2D-associated C-allele of the 
rs2237895 variant is associated with lower glucose-stimulated insulin secretion [124, 244-
246], but not with KCNQ1 expression in human islets in vitro [244]. 
 
The PPARG gene 
PPARG is the first confirmed T2D-susceptibility gene. This association was established in a 
candidate-gene study [198], based on knowledge of the receptor’s being a target for the T2D 
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thiazolidinedione drugs [247]. The association has subsequently been confirmed in GWAS 
and in a large meta-analysis comprising 32 849 T2D cases and 47 456 control subjects [205-
207, 248]. In non-diabetic Finnish subjects, the PPARG rs1801282 T2D-associated C-allele 
was observable in 82 to 85% [206, 228], which is similar to the C-allele frequency in other 
European populations [248]. 
The risk variant is non-synonymous, changing proline to alanine at position 12 (P12A), 
and has been associated with decreased transcriptional activity and increased insulin 
resistance [124, 249]. The PPARG protein is a transcription factor primarily expressed in 
adipose tissue, where it regulates adipocyte differentiation, fatty acid storage, glucose 
metabolism, insulin sensitivity, and inflammation [250-252]. 
 
The FTO gene 
FTO was initially identified as an obesity-susceptibility locus [253, 254] and subsequently as 
a T2D-associated locus [205, 254, 255] providing a molecular link between obesity and T2D. 
The association between the FTO rs9939609 intron variant and T2D was initially considered 
BMI-dependent, but two large studies have recently showed that the association remains after 
adjustments for BMI and other anthropometric measures [255, 256]. In a population-based 
Finnish sample, the frequency of the T2D-associated A-allele of the rs9939609 variant was 
39% [257], similar to the frequency in UK control subjects [205]. 
The molecular mechanism underlying the association is unclear, as the function of the 
ubiquitously expressed FTO gene product is unknown. In non-diabetic subjects and in 
population-based samples, the T2D-associated FTO variant has been associated with 
peripheral insulin resistance [124, 258-261], which is dependent on BMI in some [258-260] 
but not all studies [261]. In mice, systematic Fto overexpression results in increased energy 
intake and increased adiposity, whereas Fto knockout results in reduced fat mass [262, 263]. 
 
Table 3 Genetics of T2D – selected variants 
Locus SNP Variant RAF  Function Mechanistic link 
TCF7L2 rs7903146 Intronic 18% Transcription factor involved in glucagon and insulin secretion 
Beta-cell 
function 
SLC30A8 rs13266634 Non-synonymous R325W 61% Zinc transporter in beta cells 
Beta-cell 
function 
KCNQ1 rs2237895 Intronic 47-49% Ion-channel subunit Beta-cell function 
PPARG rs1801282 Non-synonymous P12A 82-85% 
Transcription factor involved in 
adipocyte function 
Insulin 
resistance 
FTO rs9939609 Intronic 39% Unknown BMI, insulin resistance 
RAF, risk allele frequency (in Finnish non-diabetic subjects). 
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2.6. Genetic overlap between type 1 and type 2 diabetes 
The best piece of evidence for a common genetic predisposition for T1D and T2D is the 
GLIS3 locus. Different SNPs in high LD within this locus have been associated with T1D in 
Europeans [138, 139], with T2D in Asians [264, 265], and in non-diabetic subjects associated 
with elevated fasting plasma glucose as well as reduced beta-cell function [217, 266, 267]. 
GLIS3 is a strong candidate gene for predisposition to diabetes, as it encodes a Krüppel-like 
zinc finger transcription factor highly expressed in beta cells. The transcription factor is 
proposed to be a key player in the regulation of beta-cell development and in insulin gene 
expression [268, 269]. Another possible genetic link between T1D and T2D is the PPARG 
locus. The association between the P12A variant in this gene and T2D is well-established 
[248], but the variant has also been associated with T1D in well-powered studies of up to       
7 606 T1D children [270-272]. 
Based on the other common T1D- and T2D-susceptibility gene variants, very little 
evidence exists of a direct genetic overlap between the two diabetic subtypes. A large meta-
analysis comprising more than 4 000 T2D cases and more than 5 000 control subjects 
reported no convincing associations with nine T1D-susceptibility loci, including PTPN22 and 
CTLA4 [273]. Similarly, no association was observable between the INS VNTR and T2D in a 
study comprising 1 462 patients and 4 931 control subjects [274]. In large studies of T1D 
children with a statistical power of at least 80% to detect association with an OR of 1.11, 
conflicting results have emerged for THADA and HHEX [137, 270, 275], whereas no 
association was observed for other common T2D loci, including TCF7L2, FTO, and SLC30A8 
[243, 270, 275-278]. Furthermore, no association has been observed between age at onset of 
T1D and any of the T2D-susceptibility variants [270, 275-278]. 
In line with this, neither was any association observable between variants in 11 T2D-
susceptibility genes, including FTO, KCNQ1, PPARG, SLC30A8, and TCF7L2, and 
development of islet autoantibodies in 1 350 prospectively-followed children with T1D 
parents [279]. And 1 212 patients with autoimmune diabetes showed no association with 
TCF7L2 or FTO [155]. The apparent lack of genetic overlap between T1D and T2D is, 
however, based on current knowledge of genetic susceptibility, which is limited to common 
variants; it is therefore possible that yet-unidentified variants will alter this picture. 
 
2.7. Genetics of LADA 
Current knowledge of the genetic predisposition to LADA is mainly based on small 
candidate-gene studies focusing on known T1D- or T2D-susceptibility variants. Only six of 
these studies comprise more than 100 LADA patients, and are summarised in Table 4. The 
general small sample size and heterogeneity in LADA have resulted in conflicting results. 
 
 
Review of the Literature 
 
 
29 
 
Hypothesis-free studies of the genetic background for LADA are lacking, leaving the 
possibility that LADA has a unique genetic background yet unexplored. 
 
Table 4 Summary of major LADA studies 
               LADA selection criteria  
Study Origin  n LADA Age at 
diagnosis 
Insulin free 
(months) 
Autoanti-
bodies 
Clinical 
diagnosis 
Refe-
rences 
Botnia Finland 104 No criterion* ≥6 GADA T2D [56] 
HUNT Norway 126 No criterion ≥12 GADA Not reported 
[65] 
Skåne 
Diabetes 
Register 
Sweden 164 >35 years No criterion GADA Not reported 
[280] 
Semmel-
weis Hungary 211 >35 years ≥6 
GADA/ICA/ 
IA-2A/IAA 
Not 
reported 
[281] 
NIRAD Italy 193/250 No criterion ≥6 GADA T2D 
[62, 
282, 
283] 
UKPDS‡ UK 378/400 ≥25 years ≥3 GADA/IA-2A T2D 
[284, 
285] 
*95% of the LADA patients were diagnosed at >35 years; these patients (n=99) were included in Studies I and 
III. ‡Collected from 3 different sources. 
 
Of the T1D-susceptibility gene variants, consistent association with LADA has been 
apparent for HLA, especially HLA-DQB1*02/*0302 [56, 62, 65, 280, 285]. The frequency of 
the HLA-risk genotypes is lower among LADA patients than among T1D patients who are 
diagnosed primarily at <35 years, according to some [56, 65] but not all studies [280]. The 
main protective DQB1 allele, *0602(3), is more frequent in LADA than in T1D patients [56, 
65, 280], and has been less [62, 65, 280, 285] or equally [56] frequent when compared with its 
occurrence in T2D or control subjects. Within LADA, the frequency of the HLA-risk and -
protective alleles varies according to GADA level [56, 62, 65]. The PTPN22 C1858T variant 
has been associated with LADA in general [280] or with LADA with high GADA levels 
[282]; this association is, however, not supported by recent findings [65]. Moreover, data on 
the T1D-associated INS VNTR have been conflicting: some studies show association between 
the variant and LADA [280, 284], whereas others show none [56, 65]. Only one study, 
including more than 100 LADA patients, has assessed the effect of CTLA4 and found no 
association [65]. 
With respect to the T2D-susceptibility gene variants, results are few and conflicting. 
TCF7L2 has been associated with LADA in general [280, 281], with LADA with BMI <25 
kg/m2 [281], with LADA with low GADA levels [283], or no association with LADA has 
been observable [65]. In addition, the TCF7L2 variant distinguishes middle-aged antibody-
positive patients from young antibody-positive patients [286]. Regarding other T2D-
susceptibility variants, an association has been suggested for FTO and TSPAN8 mainly in 
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LADA patients with low GADA levels, whereas no association is apparent for SLC30A8, 
PPARG, or KCNQ1 [65]. Table 5 summarises current knowledge of LADA genetics. 
 
Table 5 Genetics of LADA 
  Association 
Locus Variant LADA GADA level 
T1D-associated loci   
HLA-DQB1 *02/*0302 + + 
PTPN22 C1858T +/- + 
INS VNTR +/-  
CTLA4 CT60 (-)  
T2D-associated loci   
TCF7L2 rs7903146 +/- + 
FTO rs8050136 (+) + 
TSPAN8 rs7961581 (+) + 
SLC30A8 R325W (-)  
PPARG P12A (-)  
KCNQ1 rs2237895 (-)  
Loci associated with LADA and relevant loci showing no 
association. Parentheses indicate an observation reported 
by only one study. Only results from studies including 
more than 100 LADA patients are included. 
 
Increased knowledge of the genetic background for LADA is of great importance, 
because such data can provide clues to its underlying pathogenesis and determine whether 
LADA really is a subtype of T1D or rather a unique disease entity in the grey zone between 
T1D and T2D. 
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AIMS OF THE STUDY 
 
 
To compare patients with adult-onset T1D and LADA with respect to 
 
 clinical characteristics, namely insulin secretion and metabolic traits 
 prevalence and phenotypic associations of ZnT8A 
 association with T1D- and T2D-susceptibility gene variants 
 
To investigate the genetic heterogeneity in LADA related to 
 
 GADA level 
 family history of T1D 
 
To assess the associations of T1D-susceptibility gene variants with 
 
 phenotype of LADA patients  
 insulin secretion and GADA positivity in non-diabetic adults  
 progression to non-insulin-dependent diabetes 
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SUBJECTS AND METHODS 
 
 
1. STUDY POPULATIONS 
All studies were approved by locale ethics committees and all study subjects gave informed 
consent. 
 
1.1. The Botnia Study 
The Botnia Study was initiated in 1990 with the goal of identifying genes underlying 
metabolic defects and T2D [287]. All known T2D patients and their family members from the 
health care districts of Malax, Korsholm, Närpes, Jokobstad, and Vasa were invited to 
participate in the study. In 1994 the study was expanded phenotypically, to include also T1D 
patients, and geographically, to include patients from other parts of Finland and southern 
Sweden. In total, the Botnia Study includes 11 000 subjects from 1 400 families. 
 
1.2. The Botnia Prospective Study 
In the Botnia Prospective Study, initially non-diabetic family members and spouses (with no 
family history of diabetes) of the T2D patients from the Botnia Study were invited to follow-
up visits every 3 to 5 years [38, 54]. By 2009, about 2 800 individuals had participated in at 
least one follow-up examination. At baseline, 2 029 (73.4%) showed normal glucose 
tolerance, and 735 (26.6%) showed impaired fasting glucose or impaired glucose tolerance. 
The subjects were followed for a mean time of 8.1 years. Data on first- to third-degree family 
history of type 1 and type 2 diabetes was obtained through questionnaires or clinical 
investigation of family members. 
 
1.3. The Botnia Mix Study 
The Botnia Mix Study was set up to assess impact of family history of T1D on the phenotype 
of T2D patients. Since 2002, T2D patients with age at onset above 20 years, no insulin 
treatment within the first year of diagnosis, and with first- to third-degree relatives with T1D 
have been recruited through newspaper advertisements and via diabetes nurses around 
Finland. The total of 196 T2D patients included were interviewed by the study physician. The 
diagnosis of T1D among their relatives was verified by clinical investigation or through 
interview and/or patient records.   
 
1.4. The FinnDiane Study 
The Finnish Diabetic Nephropathy (FinnDiane) Study is nationwide and prospective, initiated 
in 1997 to identify genetic and clinical risk factors for diabetic nephropathy in patients with 
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T1D [68]. The study comprises over 4 500 T1D patients, collected from more than 70 centres 
across Finland.  
 
2. STUDY SUBJECTS 
Diabetes was diagnosed as fasting plasma glucose concentration ≥7.0 mmol/l or 2-hour 
plasma glucose concentration ≥11.1 mmol/l in compliance with WHO recommendations. T1D 
was clinically diagnosed and required a fasting C-peptide concentration of <0.2 nmol/l at the 
time of investigation, and an initiation of insulin treatment within 6 months of diagnosis. The 
LADA patients were clinically diagnosed with T2D and were additionally required to be over 
age 35 at the time of diagnosis, GADA positive, and treated without insulin for the first 6 
months after diagnosis. T2D was clinically diagnosed, and all T2D patients were GADA-
negative. 
 
2.1. Study I 
This study comprised patients from the Botnia Study with LADA (n=213), adult-onset T1D 
(>35 years at diagnosis; n=35), young-onset T1D (<20 years at diagnosis; n=158), and T2D 
(n=648), as well as 710 non-diabetic control subjects with no family history of diabetes. 
Additionally included were 222 adult-onset T1D patients from the FinnDiane Study.  
 
2.2. Study II 
This study comprised 2 764 initially non-diabetic spouses or relatives of T2D patients from 
the Botnia Prospective Study who had follow-up data available. After a mean follow-up time 
of 8.1±3.6 years, 170 (6.2%) had developed diabetes (T1D, n=3; T2D, n=133; LADA, n=34), 
and 253 (9.2%) were GADA-positive.  
 
2.3. Study III 
This study comprised patients with LADA (n=294; 312 from the Botnia Study, and 5 from 
Helsinki University Central Hospital) and with type 1 diabetes diagnosed after the age of 35 
(n=274; 29 from the Botnia Study, 222 from the FinnDiane Study, and 23 from Helsinki 
University Central Hospital), as well as non-diabetic control subjects with no family history 
of diabetes (n=537, from the Botnia Study).  
 
2.4. Unpublished data 
From the Botnia Mix Study, 196 patients with a family history of both T1D and T2D (LADA, 
n=28; T2D, n=168), 139 patients (LADA, n=6; T2D, n=133) matched for age, gender, BMI, 
and disease duration with a T2D family history only, and 274 patients from the Botnia Study 
(LADA, n=188; T2D, n=86) with a family history of T1D or T2D or both underwent study. 
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3. METABOLIC MEASUREMENTS AND ASSAYS 
 
3.1. Oral glucose tolerance test (OGTT) 
To estimate glucose tolerance, all non-insulin-dependent study subjects underwent an oral 
glucose tolerance test (OGTT), in which 75 g of glucose was administered after an overnight 
fast. Blood samples were drawn at -5, 0, 30, 60, and 120 minutes for measurement of glucose, 
insulin, and C-peptide concentrations.   
 
3.2. Basic measurements 
BMI was calculated based on measures of body weight and height as weight in kilograms 
divided by height in meters squared. Waist-hip ratio was calculated from waist circumference, 
measured at the midpoint between the iliac crest and the lowest rib, and hip circumference, 
measured at the widest part of the gluteal region. Systolic and diastolic blood pressure were 
determined as the mean of two measurements.   
Plasma glucose was measured with a glucose oxidase method applying a Beckman 
Glucose Analyzer II (Beckman Instruments, Fullerton, CA, USA). Serum insulin 
concentrations were measured either by RIA (Pharmacia, Uppsala, Sweden), with an 
interassay CV of 5%; ELISA (DAKO Diagnostics Ltd, Cambridgeshire, UK), with an 
interassay CV of 8.9%; or with the AutoDelfia immunofluorometric assay (Perkin Elmer 
Finland, Turku, Finland). Insulin concentrations obtained with the RIA and AutoDelfia 
methods were transformed to cohere with ELISA measurements. The transformation factors 
were obtained from a parallel analysis of insulin concentrations of duplicate serum samples 
from 400 subjects. The correlation coefficient between ELISA and both RIA and AutoDelfia 
was 0.98 (p<0.0001). Serum C-peptide concentrations were determined by the RIA 
radioimmunoassay with an interassay CV of 9% (Human C-peptide RIA; Linco, St. Charles, 
MO, USA). A Cobas Mira analyser (Hoffman LaRoche, Basel, Switzerland) was applied to 
measure total cholesterol, HDL-cholesterol, and triglyceride concentrations in fasting serum 
samples. HbA1c concentrations were measured by high-pressure liquid chromatography with a 
reference value of 5 to 7%.  
Insulin sensitivity was evaluated by the HOMA insulin resistance index (HOMAIR=fS-
insulin x FPG/22.5) [288] or the insulin sensitivity index (10,000/√(FPG x fS-insulin x mean 
OGTTglucose x mean OGTTinsulin)) [289]. Beta-cell function was estimated by OGTT data as 
the insulinogenic index (insulin30 – insulin0/glucose30 – glucose0) or corrected insulin 
response (CIR, 100 x insulin30/(glucose30 x (glucose30 – 3.89))) [290]. 
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3.3. Autoantibody assays 
GADA, ZnT8A, and IA-2A were measured in fasting serum samples with radiobinding assays 
using 35S-labelled protein (GAD65, IA-2ic, or ZnT8) produced by coupled in vitro 
transcription-translation as described earlier [56, 291].  
The GADA concentration was expressed as relative units (RU) until the year 2000, and 
thereafter as international units/ml (IU/ml) according to the WHO international standard. The 
positive cut-off limit was determined as the mean+3 SD in 296 healthy Finnish control 
subjects, corresponding to 5 RU or 32 IU/ml in assays employing the pEx9 plasmid and 50 
IU/ml in assays employing the pThGAD65 plasmid (after 2008). The two different scales of 
positive values prevented direct analysis of the GADA level in the whole patient material; 
instead the level was analysed separately for RU and IU/ml units based on quartiles (lowest, 5 
to 7.5 RU or 32 to 43.9 IU/ml; middle, 7.6 to 96.9 RU or 44 to 278 IU/ml; highest, >96.9 RU 
or >278 IU/ml) or the median (18.7 RU or 80.7 IU/ml). In autoantibody workshops 
(Combinatorial or the Diabetes Autoantibody Standardization Program, DASP) between 1998 
and 2005, the GADA assay showed 82 to 84% sensitivity and 95 to 96% specificity [292]. 
The ZnT8ARW assay employed the chimeric recombinant plasmid (provided by J. 
Hutton, University of Colorado, Denver, USA) containing the C-terminal part (aa 268-369) of 
ZnT8-325R and ZnT8-325W for initial ZnT8A screening. ZnT8AR and ZnT8AW reactivity 
was measured in ZnT8ARW-positive samples. ZnT8A concentrations were expressed as RU 
derived from a standard curve of pooled strongly ZnT8A-positive samples diluted in normal 
human serum. The positive cut-off limits were 0.61 RU (ZnT8ARW), 1.97 RU (ZnT8AR), and 
3.40 RU (ZnT8AW), corresponding to the 99th percentile in a combined sample of non-
diabetic Finnish children and adolescents (n=250) as well as the DASP control panel (n=100). 
In the 2009 DASP workshop, all three ZnT8A assays showed 100% specificity and 63% 
(ZnT8ARW), 48% (ZnT8AR), and 34% (ZnT8AW) sensitivity [293]. 
IA-2A concentration was expressed as RU with a positive cut-off limit of 2.5 RU, 
representing the mean+3 SD in 155 healthy Finnish control subjects. In DASP workshops 
between 2002 and 2005, the assay showed 62 to 70% sensitivity and 99 to 100% specificity 
[292]. 
 
4. GENOTYPING 
To assess the contribution of T1D- and T2D-susceptibility gene variants in LADA and adult-
onset T1D, we genotyped variants chosen based on effect size and knowledge of validation in 
Finns and other European populations at the time when the study was planned. The 
contribution of T1D susceptibility was represented by variants in HLA-DQB1, PTPN22, INS, 
and CTLA4. The contribution of T2D-susceptibility genes affecting beta-cell function was 
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represented by variants in TCF7L2, SLC30A8, and KCNQ1; and T2D-susceptibility genes 
affecting insulin resistance were represented by variants in PPARG and FTO.  
 
4.1. HLA-DQB1 automated method (Studies I, III, and unpublished data) 
Applying the automated method [294], the second exon of HLA-DQB1 was PCR amplified 
and subsequently hybridized with lanthanide (III) chelate-labelled DNA probes specific for 
the HLA-DQB1*02, *0301, *0302, *0602, and *0603 alleles. Hybridization was evaluated by 
time-resolved fluorescence (Delfia Research Fluorometer, Wallac OY, Turku, Finland).  
 
4.2. Taqman allelic discrimination (HLA: Study II; other SNPs: Studies II, III, and 
unpublished data) 
Genotyping of variants in PTPN22 (rs2476601), INS (rs689), CTLA4 (rs3087243), HLA-
DQA1-DQB1 (rs2187668, tagging DQA1*05/DQB1*02 (DQ2.5), and rs7454108 tagging 
DQA1*03/DQB1*0302 (DQ8)), TCF7L2 (rs7903146), SLC30A8 (rs13266634), KCNQ1 
(rs2237895), PPARG (rs1801282), and FTO (rs9939609) was carried out by fluorogenic 5’ 
nuclease allelic discrimination chemistry (TaqMan®) on an ABI Prism® 7900 Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA). The assay mix containing 
primers and probes was designed by Applied Biosystems.  
 
4.3. Genetic risk scores 
Study I 
The combined effect of the T1D-susceptibility variants in HLA-DQB1, PTPN22, INS, and 
CTLA4 was assessed as a genetic risk score. The number of risk genotypes (HLA-
DQB1*02/*0302 and *0302/X, INS AA, PTPN22 CT/TT, and CTLA4 GG) was counted (0-4), 
and subjects having 0, 1, or ≥2 risk genotypes were grouped. Subjects with one or more 
missing genotypes (n=33) were excluded from analysis. 
 
Study II 
The T1D-susceptibility variants in HLA-DQ, PTPN22, INS, and CTLA4 were combined in a 
genetic risk score where each variant contributed in correspondence to its level of effect size. 
DQ2.5/DQ2.5, DQ2.5/DQX, INS AA, PTPN22 CT/TT, and CTLA4 GG each contributed with 
one, DQ8/DQ8 and DQ8/DQX with two, and DQ2.5/DQ8 with three points to the risk score. 
For the analyses, subjects were divided into groups having a genetic risk score (0-6) of ≤1, 2 
to 3, or ≥4. Subjects with one or more missing genotypes (n=65) were excluded from analysis. 
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5. STATISTICAL ANALYSES 
All statistical analyses were performed with the Statistical Package for Social Science 
software (SPSS, Chicago, IL, USA). A p-value <0.05 was considered significant. All p-values 
presented are uncorrected for multiple testing. Differences in genotype distributions as well as 
GADA and ZnT8A prevalence were analysed with the chi-squared test or logistic regression. 
Differences in quantitative traits including ZnT8A level were assessed with the Mann-
Whitney U-test or a general linear model after logarithmic transformation when appropriate. 
A Cox regression analysis was applied to assess the risk of developing non-insulin-dependent 
diabetes from baseline to follow-up.  
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RESULTS 
 
 
1. CLINICAL COMPARISON OF ADULT-ONSET T1D AND LADA (Studies I and 
III) 
Adult-onset T1D patients diagnosed above the age of 35 years (T1D>35) were similar to T1D 
patients diagnosed before age 20 (T1D<20) regarding metabolic traits (BMI, triglycerides as 
well as HDL- and LDL-cholesterol) and level of hyperglycaemia (HbA1c; Figure 7), despite 
large differences in age (at diagnosis, mean±SD: 41.8±6.6 vs. 10.0±5.0 years; at investigation, 
53.5±8.7 vs. 33.6±13.7 years) and duration (11.7 ±7.9 vs. 23.7±13.0 years).  
LADA patients’ figures were intermediate between those of T2D and T1D>35 patients 
both metabolically and with respect to level of hyperglycaemia (HbA1c: LADA vs. T2D, 
7.9±0.2% vs. 7.4±0.1%, p=0.01; vs. T1D>35, 8.5±0.1%, p<0.0001; Figure 7). The beta-cell 
function also differed between patient groups; the level of insulin secretion was significantly 
lower in LADA than in T2D patients (fS-C-peptide, 0.49±0.03 vs. 0.67±0.02 nmol/l, 
p<0.00001; Figure 7), but was significantly higher than in T1D>35 patients (p<0.00001), 
whose fS-C-peptide by criterion was < 0.2 nmol/l. 
 
 
Figure 7 Clinical characteristics of patients with T2D, LADA, T1D>35 (FPG data were not 
available), and T1D<20. Data are mean values (SEM). * BMI, LADA vs. T2D/T1D>35: 
p<0.0001/p<0.001; HbA1c, p=0.01/p<0.0001; FPG, p<0.0001; triglycerides, p<0.00001; LDL-
cholesterol, p<0.00001; fS-C-peptide, p<0.00001. p-values obtained with a general linear model 
adjusted for age (Study I). 
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LADA and T1D>35 patients also differed regarding prevalence of ZnT8A. Hence, 
ZnT8A were observed more often in LADA patients than in T1D>35 patients (ZnT8ARW: 
34.3% vs. 18.7%, p<0.0001; ZnT8AR: 26.9% vs. 8.0%, p=0.0002; ZnT8AW: 26.1% vs. 6.1%, 
p<0.00001). Among ZnT8A-positive subjects, the autoantibody levels in LADA and T1D>35 
patients were similar (data not shown). In T1D>35 patients, ZnT8A prevalence was negatively 
correlated with disease duration (p<0.0001; Figure 8), and ZnT8A specificity was associated 
with SLC30A8 R325W genotype; the CC genotype of the SLC30A8 R325W variant was 
associated with presence of ZnT8AR (SLC30A8 CC vs. CT vs. TT: 16.1% vs. 2.5% vs. 6.5%, 
p=0.001), whereas the TT genotype was associated with the presence of ZnT8AW (SLC30A8 
CC vs. CT vs. TT: 3.4% vs. 3.4% vs. 17.4%, p=0.001; data not shown). Among LADA 
patients, the ZnT8A prevalence was not associated with disease duration (Figure 8), nor was 
ZnT8A specificity associated with SLC30A8 R325W genotype (data not shown).  
 
 
Figure 8 Prevalence of ZnT8A according to duration in LADA (n: ≤5 years, 142; >5-10 years, 58; 
>10 years, 82) and in T1D>35 (133, 93, and 36) patients. * p<0.0001, assessed with the Chi-squared 
test (Study III). 
 
 
ZnT8A positivity was not a major phenotypic determinant in LADA or T1D>35. ZnT8A 
were associated with older age at diagnosis among LADA patients (ZnT8A-positive vs.          
-negative, 60.0 (17.0) vs. 53.0 (16.3) years, p=0.002), but not with reduced insulin secretion 
or insulin sensitivity in either LADA or T1D>35 patients (data not shown). Among LADA 
patients, ZnT8A positivity in combination with a high GADA level (>median) signified a 
strong autoimmune profile, which was associated with reduced insulin secretion (fS-C-
peptide, p<0.0001) and lower BMI (p=0.011; Table 6). 
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Table 6 Clinical characteristics by autoimmune profile in LADA patients 
 Autoimmune profile  
 Strong Weak p-value 
n 45 88  
Age at diagnosis (years) 51.0 (19.5) 53.5 (17.8) 0.614 
BMI (kg/m2) 25.73 (4.41) 27.53 (5.19) 0.011 
Duration (years) 4.0 (10.8) 6.0 (10.0) 0.345 
FPG (mmol/l) 8.8 (5.1) 8.1 (5.9) 0.734 
Insulinogenic index 2.83 (3.94) 4.87 (10.15) 0.257 
CIR 26 (41) 34 (70) 0.178 
fS-C-peptide (nmol/l) 0.30 (0.46) 0.61 (0.51) <0.0001 
Data are median (interquartile range). Differences between patients with a 
strong (GADA >median and ZnT8A+) and a weak (GADA <median and 
ZnT8A-) autoimmune profile were assessed with the Mann-Whitney U-test 
(Study III). 
 
2. GENETIC COMPARISON OF ADULT-ONSET T1D AND LADA (Studies I, III, 
and unpublished data) 
The T1D-risk variants were associated with both T1D<20 and T1D>35. Compared with the 
frequency in non-diabetic control subjects, HLA-DQB1-, PTPN22-, INS-, and CTLA4-risk 
genotypes were significantly more frequent in both T1D<20 and T1D>35 patients (HLA-
DQB1*02/*0302 or *0302/X, p<0.0000001 for both; PTPN22 CT/TT, p=0.006 and 
p<0.000001; INS I/I, p=0.0002 and p<0.000001, CTLA4 GG, p=0.008 and p=0.003). The 
HLA-DQB1-protective genotypes were equally rare in both T1D<20 (3.8%) and T1D>35 
patients (2.3%), and the frequency in both groups of T1D patients differed significantly from 
their frequency in non-diabetic control subjects (*0602(3)/X or *0602(3)/*0301, p<0.0000001 
for both; Figure 9).  
 
 
Figure 9 Genotype distribution of T1D-susceptibility variants in T1D<20 (n=158), T1D>35 (n=257), 
LADA (n=213), and T2D (n=648) patients, as well as non-diabetic control subjects (n=710). * 
Significant difference in genotype distribution compared with that of the control subjects: T1D<20, 
p≤0.008; T1D>35, p≤0.003; LADA, p≤0.03. ‡ significant differences in genotype distribution 
between LADA and T1D>35 and/or T2D patients, p≤0.03 (Study I). HLA-DQB1: risk, *02/*0302 or 
*0302/X; protective, *0602(3)/X or *0602(3)/*0301. 
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Among the T1D patients, association with age at diagnosis was observed for HLA-
DQB1, whether analysed as genotype frequency in T1D<20 vs. T1D>35 (*02/*0302 or 
*0302/X, 75.3% vs. 50.2%, p<0.000001), or with age at diagnosis as a continuous variable in 
HLA-DQB1 risk vs. neutral vs. protective genotype carriers (mean±SEM, 25.98±1.04 vs. 
35.60±1.22 vs. 29.69±5.22 years, p=0.004). The frequencies of PTPN22-, INS-, and CTLA4-
risk genotypes were similar in T1D<20 and T1D>35 patients (Figure 9). Two T2D-susceptibility 
gene variants, TCF7L2 rs7903146 and SLC30A8 R325W, were genotyped in the T1D>35 
patients, but we observed no association for either of these variants (Figure 10). 
In LADA patients, significant associations appeared for HLA-DQB1*02/*0302 or 
*0302/X genotypes (control subjects vs. LADA patients: 14.1% vs. 32.2%, OR (95% CI): 
2.90 (2.03-4.15), p<0.0000001) and the PTPN22-CT/TT genotypes (20.9% vs. 28.1%, OR: 
1.48 (1.04-2.10), p=0.03). The frequency of the protective HLA-DQB1*0602(3)/X or 
*0602(3)/*0301 genotypes was significantly lower in LADA patients than in non-diabetic 
control subjects (19.0% vs. 30.7%, OR: 0.53 (0.36-0.77), p=0.001). No association with 
LADA emerged for INS (I/I: 59.1% vs. 58.7%) or CTLA4 (GG: 37.6% vs. 45.0%; Figure 9).  
The T1D-susceptibility genotype frequencies in LADA patients differed significantly 
from the frequencies observed in T1D>35 with respect to HLA-DQB1 (p=0.00009), PTPN22 
(p=0.03), and INS (p=0.00002), as well as the HLA-DQB1-protective genotypes 
(p<0.000001). Compared with T2D patients, the frequencies in LADA patients differed with 
respect to HLA-DQB1-risk (p<0.000001) and -protective genotypes (p=0.0005), as well as 
PTPN22-risk genotypes (p=0.01). The frequency of the CTLA4 GG risk genotype in LADA 
patients did not differ significantly from its frequency in either T1D>35 or T2D patients 
(Figure 9). 
 
 
Figure 10 Genotype distribution of T2D-risk variants in T1D>35 (TCF7L2, n=257; SLC30A8, 
n=274), LADA (SLC30A8, n=294; all other, n=213), and T2D (n=648) patients, as well as non-
diabetic control subjects (SLC30A8, n=537; all other, n=710). * Significant difference in genotype 
distribution compared with control subjects, TCF7L2: LADA, p=0.001; T2D, p=0.0001; SLC30A8: 
T2D, p=0.026; FTO: T2D, p=0.003. ‡ significant differences in genotype distribution between 
LADA and T1D>35 patients, TCF7L2: p=0.0007; SLC30A8: p=0.049 (Study III, unpublished data). 
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The association of T2D-susceptibility variants in TCF7L2, SLC30A8, KCNQ1, PPARG, 
and FTO was also assessed in LADA patients. Compared with non-diabetic control subjects, 
the frequency of the T2D-associated TCF7L2 genotypes was significantly higher in LADA 
patients (CT/TT, 30.8% vs. 42.7%, OR: 1.67 (1.22-2.28), p=0.001), whereas no differences 
appeared for SLC30A8 (CC, 38.2% vs. 43.2%), KCNQ1 (CC, 23.8% vs. 21.6%), PPARG (CC, 
74.7% vs. 71.9%), or FTO (TA/AA, 60.6% vs. 58.3%; Figure 10). Regarding TCF7L2, BMI 
was similar in LADA patients carrying the CT/TT and the CC genotypes (27.40 vs. 27.25 
kg/m2), and the genotype frequencies were similar in non-overweight (BMI <25 kg/m2, 
CT/TT: 44.9%) and overweight LADA patients (BMI ≥25 kg/m2, 38.2%; unpublished 
observation). 
The frequencies of TCF7L2- and SLC30A8-risk genotypes in LADA patients differed 
significantly from frequencies observed in T1D>35 patients (p=0.0007 and p=0.049, 
respectively), whereas only the FTO-risk genotype frequency differed from the frequency in 
T2D patients (LADA vs. T2D, TA/AA: 58.3% vs. 70.6%, p=0.006 adjusted for BMI, Figure 
10). 
 
3. GENETIC HETEROGENEITY IN LADA (Studies I, III, and unpublished data) 
Among LADA patients, GADA level was associated with clinical differences. Comparing 
clinical trait values across three groups, comprising patients with GADA levels in the lowest 
quartile (LADAlow; 32-43.9 IU/ml), patients with GADA levels in the two middle quartiles 
(LADAmid; 44-278 IU/ml), and patients with GADA levels in the highest quartile (LADAhigh; 
>278 IU/ml), insulin secretion (LADAlow vs. LADAmid vs. LADAhigh, mean±SD, fS-C-
peptide: 0.56±0.35 vs. 0.54±0.47 vs. 0.31±0.33 nmol/l, p=0.001), lipid concentrations (HDL-
cholesterol: 1.26±0.36 vs. 1.32±0.35 vs. 1.45±0.38 mmol/l, p=0.03; triglycerides: 1.74±1.02 
vs. 1.60±0.81 vs. 1.51±1.64 mmol/l, p=0.04; LDL-cholesterol: 3.78±0.99 vs. 3.69±0.82 vs. 
3.29±0.78 mmol/l, p=0.005), age at investigation (67.2±10.1 vs. 61.5±12.9 vs. 62.3±11.2 
years, p=0.02), and BMI (28.3±4.4vs. 27.4±5.0 vs. 25.8±4.0 kg/m2, p=0.01) differed 
significantly. The LADAhigh patients were more T1D-like, but differed significantly from the 
T1D>35 patients regarding fS-C-peptide levels (p=0.001). Conversely, the LADAlow patients 
were more T2D-like, but also between these two groups the fS-C-peptide levels differed 
significantly (p=0.01).  
Among LADA patients, the frequency of the T1D-susceptibility variants in HLA-DQB1, 
PTPN22, INS, and CTLA4 varied by GADA level and was highest in the LADAhigh patients. 
The difference across the GADA quartiles was, however, only significant for HLA-DQB1-risk 
(*02/*0302 or *0302/X, LADAhigh vs. LADAmid vs. LADAlow, 44.2% vs. 32.4% vs. 19.6%, 
p=0.03) and -protective genotypes (*0602(3)/X or *0602(3)/*0301, 13.5% vs. 14.8% vs. 
33.3%, p=0.01, Figure 11).  
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Figure 11 Genotype distribution of T1D-risk variants in LADA patients with GADA levels in the 
highest quartile (LADAhigh, n=52), the two middle quartiles (LADAmid, n=109), and the lowest 
quartile (LADAlow, n=52). *LADAhigh vs. non-diabetic control subjects, PTPN22: p=0.009; CTLA4: 
p=0.02; across the GADA-level groups, HLA-DQB1 risk: p=0.03; HLA-DQB1 protective: p=0.01. 
HLA-DQB1, risk: *02/*0302 or *0302/X, protective: *0602(3)/X or *0602(3)/*0301 (Study I). 
 
 
The PTPN22-risk genotype frequency did not differ between LADAmid/LADAlow and 
the control subjects (25.3% vs. 20.9%, p=0.227); hence the association was restricted to the 
LADAhigh group (p=0.009). Similarly, for CTLA4, an association emerged in the LADAhigh 
subjects (control subjects vs. LADAhigh, GG: 37.6% vs. 53.8%, p=0.02), even though no 
association occurred in comparison of control subjects and the entire LADA sample. For INS, 
not even the LADAhigh group differed from the control group (Figures 9 and 11). The T1D-
risk genotype frequencies observed in LADAhigh were similar to frequencies in the T1D>35 
patients; between the two groups, only the frequency of the HLA-DQB1-protective genotypes 
differed significantly (p=0.0003). Conversely, the genotype frequencies in LADAlow were 
similar to those observed in T2D patients (Figures 9 and 11). 
The T2D-susceptibility gene variants in TCF7L2, KCNQ1, and PPARG made no 
contribution to heterogeneity in LADA, as the risk-genotype frequencies of these variants 
were independent of GADA level (Figure 12). However, compared with LADAmid/LADAlow, 
the SLC30A8 CC-risk genotype was significantly lower among LADAhigh patients (45.6% vs. 
32.0%, p=0.04). Compared with T2D patients, both FTO (p=0.009 adjusted for BMI) and 
SLC30A8 (p=0.029) risk-genotype frequencies were significantly lower in LADAhigh patients 
(unpublished data). And after splitting the LADA patients according to the GADA median, 
the SLC30A8 CC genotype was significantly associated with LADA that had GADA levels 
below the median (LADA vs. control subjects, 47.4% vs. 38.2%, OR: 1.46 (1.0-2.1), 
p=0.049). 
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Figure 12 Genotype distribution of T2D-susceptibility variants in LADA patients with GADA 
levels in the highest quartile (LADAhigh, n=52), the two middle quartiles (LADAmid, n=109), or the 
lowest quartile (LADAlow, n=52). *SLC30A8: LADAhigh vs. LADAmid/LADAlow, p=0.04 vs. T2D, 
p=0.029; FTO: LADAhigh vs. T2D, p=0.009 (Study III and unpublished data). 
 
 
Family history of T1D was also associated with genetic heterogeneity in LADA 
patients. Comparing LADA patients with a family history of both T1D and T2D with LADA 
patients having a family history of T2D only, the frequency of HLA-DQB1*02/*0302 or 
*0302/X genotypes was higher (51.2% vs. 29.6%, p=0.001) and the frequency of TCF7L2 
CT/TT genotypes was lower (34.5% vs. 48.8%, p=0.05). Similar to HLA-DQB1, the PTPN22 
CT/TT genotypes were higher in patients with a family history of T1D and T2D than in 
patients with T2D only (23.9% vs. 33.7%); this difference was, however, non-significant. The 
frequency of INS-, CTLA4-, SLC30A8-, KCNQ1-, PPARG-, and FTO-risk genotypes was 
independent of family history (Unpublished data, not shown).  
Similar to the observation in LADA patients, family history of T1D was also associated 
with a higher frequency of HLA-DQB1-risk genotypes among the T2D patients (HLA-
DQB1*02/*0302 or *0302, family history of T2D vs. family history of T1D and T2D: 12.9% 
vs. 23.0%, p=0.03). No differences in genotype frequencies were observable for PTNP22, 
INS, CTLA4, or any of the T2D-susceptibility variants regarding family history in T2D 
patients (Unpublished data, not shown). 
 
4. PHENOTYPIC ASSOCIATIONS OF T1D- AND T2D-SUSCEPTIBILITY 
VARIANTS (Studies I, II, III, and unpublished data) 
T1D-associated risk genotypes did not affect the clinical phenotype of the T1D patients, but 
were associated with the clinical phenotype of LADA and T2D patients. Among LADA 
patients, an increasing number of risk genotypes correlated with reduced insulin secretion (fS-
C-peptide, 0 vs. 1 vs. ≥2 risk genotypes: 0.68 (0.65) vs. 0.44 (0.43) vs. 0.31 (0.60) nmol/l, 
p=0.015) and younger age at diagnosis (62.0 (17.5) vs. 54.5 (18.3) vs. 53.0 (18.5) years, 
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p=0.04). Among T2D patients, a similar trend appeared with respect to the fS-C-peptide (0.69 
(0.43) vs. 0.68 (0.46) vs. 0.56 (0.51) nmol/l, p=0.027).  
In the 2 764 initially non-diabetic subjects of the Botnia Prospective Study, T1D-
associated risk variants in HLA-DQ, PTPN22, INS, and CTLA4 were also associated with the 
clinical phenotype. At baseline, carrying a larger number of risk genotypes was associated 
with reduced insulin secretion (genetic risk score of ≤1 vs. 2 to 3 vs. ≥4, insulinogenic index: 
13.27 (16.27) vs. 12.69 (15.27) vs. 10.98 (13.06), p=0.02) and enhanced insulin sensitivity 
(insulin sensitivity index: 142 (111) vs. 144 (118) vs. 157 (127), p=0.01; Figure 13). During a 
mean follow-up of 8.1±3.6 years, BMI increased and insulin sensitivity decreased 
independent of the risk genotypes, but subjects with a high genetic risk score showed reduced 
levels of insulin secretion at follow-up; hence, these subjects were less able to compensate for 
the increased demand for insulin (Figure 13).  
 
 
 
 
Figure 13 Effect of T1D-susceptibility variants on A) BMI, B) insulin sensitivity, and C) insulin 
secretion at baseline and follow-up. Data are mean values (SEM) logarithmically transformed for 
the insulin sensitivity index and the insulinogenic index. The group with a genetic risk score ≤1 
(n=1 116) is compared with the group with a genetic risk score ≥4 (n=297) by a general linear 
model, and asterisks mark significant differences. Insulin sensitivity index at baseline, p=0.004; 
insulinogenic index at baseline, p=0.017 (Study II). 
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In these non-diabetic subjects, HLA-DQB1- and PTPN22-risk genotypes were, 
furthermore, associated with GADA (HLA-DQ2.5/DQ8 or DQ8, OR: 1.7 (1.3-2.3), p=0.0004; 
PTPN22 CT/TT, OR: 1.6 (1.2-2.2), p=0.003; Figure 14). Among the GADA-positive subjects, 
the HLA-DQ2.5/DQ8 genotype was associated with a higher GADA level (p=0.004; data not 
shown). For CTLA4- and INS-risk genotypes, we observed no association with GADA (Figure 
14). Compared with LADA patients, the frequency of the HLA-DQB1- and PTPN22-risk 
genotypes in the non-diabetic GADA-positive subjects was similar (HLA-DQB1: (*02/*0302 
or *0302/X) 32.2% vs. (corresponding DQ2.5/DQ8 or DQ8) 31.2%; PTPN22 CT/TT: 28.1% 
vs. 28.0%; Figures 9 and 14). 
 
 
 
Figure 14 Frequency of GADA-positive subjects according to genotype. HLA-DQ risk: 
DQ2.5/DQ8 or DQ8, p=0.0004; PTPN22 risk: CT/TT, p=0.003; INS risk: I/I; CTLA4 risk: GG. 
Differences were assessed with logistic regression (Study II). 
 
Family history of T1D (FHT1) was also associated with GADA in the non-diabetic 
subjects. With respect to HLA-DQ and PTPN22, the highest prevalence of GADA positivity 
appeared in subjects having both the risk genotype and FHT1 (Non-risk genotype and FHT1- 
vs. risk genotype and FHT1+; HLA-DQ, 7.7% vs. 16.3%, OR: 2.3 (1.5-3.6), p=0.0002; 
PTPN22, 7.8% vs. 20.5%, OR: 3.1 (1.9-5.0), p<0.00001; Table 7). The INS-risk genotype was 
only associated with GADA in combination with FHT1 (9.2% vs. 16.5%, OR: 1.9 (1.3-2.9), 
p=0.001), whereas no association between CTLA4 and GADA was observable regardless of 
family history (Table 7). 
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Table 7 GADA prevalence by genotype and family history of T1D 
Locus Genotype/FH GADA+ n (%) OR (95% CI) p-value 
HLA        Non-risk/- 141 (7.7) 1.0 - 
 Non-risk/+ 31 (12.2) 1.7 (1.1-2.5) 0.016 
 Risk/- 50 (10.8) 1.4 (1.0-2.0) 0.034 
 Risk/+ 28 (16.3) 2.3 (1.5-3.6) 0.0002 
PTPN22 Non-risk/-          144 (7.8) 1.0 - 
 Non-risk/+ 36 (11.3) 1.5 (1.0-2.2) 0.036 
 Risk/- 47 (10.4) 1.4 (1.0-1.9) 0.072 
 Risk/+ 23 (20.5) 3.1 (1.9-5.0) <0.00001 
INS Non-risk/-          89 (9.2) 1.0 - 
 Non-risk/+ 17 (9.7) 1.1 (0.6-1.8) 0.845 
 Risk/- 101 (7.6) 0.8 (0.6-1.1) 0.168 
 Risk/+ 41 (16.5) 1.9 (1.3-2.9) 0.001 
CTLA4 Non-risk/-          126 (9.2) 1.0 - 
 Non-risk/+ 37 (14.5) 1.7 (1.1-2.5) 0.010 
 Risk/- 65 (7.0) 0.8 (0.5-1.0) 0.071 
 Risk/+ 22 (12.9) 1.5 (0.9-2.4) 0.124 
Differences between groups analysed with logistic regression; p-values (un-
adjusted) compare the group with non-risk genotype and no family history of 
type 1 diabetes (FHT1-) against the other groups for each gene variant (Study II). 
 
In 2 764 initially non-diabetic subjects, a Cox regression analysis including known 
clinical T2D-risk factors (gender, age, BMI, FPG, GADA level, family history of T2D, and 
FHT1) and the T1D-associated gene variants, showed no association for any of the T1D-risk 
variants (HLA-DQ2.5/DQ8, HLA-DQ8, HLA-DQ2.5, PTPN22 CT/TT, INS AA, and CTLA4 
GG, HR: 1.0-1.2, p=0.455-0.977) with development of non-insulin-dependent diabetes. This 
analysis further showed that the previously reported association between FHT1 and 
development of non-insulin-dependent diabetes was independent of the T1D-associated 
variants (data not shown). In the cross-sectional study sample, as well, frequency of the T1D-
risk variants and the HLA-DQB1-protective genotypes were similar in control subjects and in 
T2D patients (Figure 9).  
Phenotypic associations were also assessed for the T2D-susceptibility R325W variant in 
SLC30A8. The T2D-associated SLC30A8 genotypes were associated with reduced insulin 
secretion in both groups of non-diabetic subjects (incremental AUC S-C-peptide, CC/CT vs. 
TT: 1.88 (1.68) vs. 3.43 (1.88) nmol/l, p=0.049) and of LADA patients (2.34 (2.43) vs. 3.77 
(3.76) nmol/l, p=0.036).  
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DISCUSSION  
 
 
Genetic research was revolutionised by the advent of GWAS. In the last five years, this 
hypothesis-free approach has contributed a large number of novel susceptibility loci for both 
T1D and T2D, discoveries leading to new knowledge regarding the biological pathways 
underlying diabetes. Knowledge of the genetics underlying adult-onset T1D and LADA is, on 
the other hand, sparse. The genetics of T1D has thus far primarily been investigated in 
children <15 years; some studies have included a small group with T1D diagnosed >20 [20, 
21, 148, 153] or >30 years [149, 150, 152, 154, 155], whereas research on large distinct 
groups of T1D patients >35 are lacking. With respect to the genetics of LADA, only a handful 
of studies have included 100 or more patients, with the observations from these LADA 
studies being extremely difficult to compare, as no consensus exists as to LADA diagnosis. 
The same problems apply to the clinical characterisation of LADA and of adult-onset T1D. 
Hence, based on earlier data, whether differences observed between LADA and T1D are 
solely attributable to differences in age at onset or reflections of true pathophysiologically 
differences is still an open question. 
 
1. CLINICAL COMPARISON OF ADULT-ONSET T1D AND LADA 
Our adult-onset T1D patients were comparable to young-onset T1D patients regarding 
metabolic traits and level of insulin secretion, which indicates that despite their marked 
differences in age at diagnosis, the pathogenesis underlying T1D patients diagnosed at <20 
and >35 years is similar. These similarities were observed even though disease duration was 
significantly longer in the T1D patients diagnosed at <20 years. It is, however, possible that 
differences would have been observable at the time of diagnosis, as suggested by a report of 
lower insulin secretion in newly diagnosed T1D patients <20 years than in patients >20 years 
[20, 21].  
Regarding metabolic traits and level of insulin secretion, LADA patients and T1D 
patients with age at diagnosis falling within a similar age-range clearly differed. This finding 
emphasises that differences observed in studies comparing LADA and T1D patients mainly 
diagnosed at <20 years [56, 70-72, 77] is more than an age-related phenomenon.  
Also with respect to ZnT8A, patients with LADA and adult-onset T1D differed. Hence, 
ZnT8A were more prevalent among LADA (34%) than among adult-onset T1D patients 
(19%). The prevalence observed in T1D>35 patients was similar to the reported frequency of 
24% in patients diagnosed at >30 years [26]. In our study, ZnT8A were not associated with 
age at diagnosis in T1D patients diagnosed at >35 years. But when looking at a larger age-at-
onset spectrum, ZnT8A seem to be associated with younger age at onset, with a peak 
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prevalence in late adolescence of 80% [26, 242, 295, 296]. Overall, the prevalence observed 
in the LADA patients (34%) falls within the range of previous studies (4% to 42%) [296-
300].Variation among studies is probably due to small sample sizes (ranging from 47 to 193) 
and different criteria for LADA diagnosis, but is unlikely to be due to differences in GADA 
level, as we observed no correlation between ZnT8A and GADA level in the LADA patients. 
Furthermore, we observed no correlation between ZnT8A positivity and the phenotype of 
LADA patients; hence, despite the higher prevalence in LADA compared with that in adult-
onset T1D patients, ZnT8A have limited value as a marker of progression to insulin therapy in 
LADA. This notion is in line with observations in the NIRAD Study [298]. However, ZnT8A 
positivity combined with an increased GADA level was associated with a more T1D-like 
phenotype in LADA patients with lower BMI and lower C-peptide levels. 
Among T1D>35 patients, the ZnT8A prevalence was negatively correlated with disease 
duration, in line with observations in younger T1D patients [25]. The reduction in ZnT8A 
positivity may be a consequence of the progressive beta-cell loss resulting in lower amounts 
of ZnT8 antigens. On the contrary, we observed no correlation between ZnT8A prevalence 
and LADA duration. This lack of correlation may be a reflection of the lower degree of beta-
cell destruction in these patients when compared with T1D patients or may indicate that 
ZnT8A are more persistent in LADA than in T1D>35 patients. This observation is, however, 
based on cross-sectional data, and needs to be replicated in a prospective study with several 
longitudinal ZnT8A measurements for each patient.  
In relation to ZnT8A reactivity, the genotype of the R325W variant in SLC30A8 
encoding the ZnT8 protein is extremely interesting. This protein contains discrete epitopes 
depending on R325W genotype, giving rise to different ZnT8A subtypes, namely ZnT8AR 
and ZnT8AW (recognising the arginine and tryptophan epitope, respectively). Among the 
adult-onset T1D patients, the R325W variant was associated with ZnT8A antigen specificity. 
Hence, the arginine-coding CC genotype was associated with prevalence of the ZnT8AR 
subtype, and the tryptophan-coding TT genotype was associated with the ZnT8AW subtype in 
line with reports in T1D children [291]. The SLC30A8 R325W genotype was not associated 
with the ZnT8A specificity among the LADA patients. This may indicate that the ZnT8A 
epitopes in T1D and LADA differ, and that the ZnT8A binding in LADA patients is less 
specific. In summary, the ZnT8A data indicate that LADA and adult-onset T1D patients differ 
immunologically, and our clinical data support the notion that LADA is a phenotype with a 
lower degree of beta-cell destruction than in T1D even when diagnosed at >35 years.  
 
2. GENETIC COMPARISON OF ADULT-ONSET T1D AND LADA 
The T1D-susceptibility variants in HLA-DQB1, PTPN22, INS, and CTLA4 were all 
significantly associated with adult-onset T1D, as well as with T1D diagnosed at <20 years. 
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Genetic studies on T1D patients diagnosed at >35 years are few, but in children [136] and 
adults mainly diagnosed at <35 years, HLA-DQB1 have consistently been associated with 
T1D [20, 21, 148-154]. With respect to PTPN22, INS, and CTLA4, association with T1D has 
been reported in children [136] and for PTPN22 and INS, an association has also been evident 
in young adults aged between 15 and 40 years at diagnosis [154].  
A study on twins indicates that compared with young-onset patients, the genetic 
component in T1D development in adult-onset patients is weaker [91]. This notion is 
supported by our results on HLA-DQB1, where the risk-genotype frequency was significantly 
higher among T1D patients diagnosed at <20 years than in patients diagnosed at >35 years, 
and by previous comparisons mainly of T1D patients diagnosed under and over the age of 20 
years [20, 21, 148-154]. Variation in HLA-DQB1-risk genotype frequencies between 
populations and variation in age-at-onset limits for the groups included in each study, 
however, makes it difficult directly to compare the frequencies in our T1D patients >35 years 
with the frequencies in other reports. With respect to PTPN22, INS, and CTLA4, the 
frequencies of the risk genotypes were similar in T1D patients at >35 and at <20 years at 
diagnosis and, thus were not associated with age at onset of T1D. This conclusion is 
supported by observations in T1D patients diagnosed at between 15 and 40 years [154], 
whereas in T1D children, association with age at diagnosis has been apparent for INS [166] 
and for PTPN22 according to one [165] but not all studies [161, 166]. Furthermore, the 
protective HLA-DQB1*0602(3)/X or *0602(3)/*0301 genotypes were equally rare in T1D 
patients >35 (2.3%) and <20 years (3.8%). Taken together, our data thus suggest that besides 
HLA-DQB1*02/*0302 and *0302, the genetic predisposition toward T1D in children and 
adults is similar. Differing ages at onset in T1D might instead be due to differing overall 
genetic load or different accumulation of environmental exposures. It is, however, possible 
that the genetic basis for a delayed age at onset is represented by gene variants exclusively 
associated with adult-onset T1D. This possibility is thus far barely explored.  
HLA-DQB1*02/*0302 or *0302 and PTPN22-CT/TT genotypes were significantly 
associated with LADA in general, and CTLA4 CT60 GG with LADA with high GADA levels. 
With respect to HLA-DQB1, this is in line with others’ reports [56, 65, 280, 285], and with 
respect to PTPN22 the association is in agreement with the Skåne Diabetes Register Study 
[280] but in disagreement with the HUNT Study [65]. This disagreement is likely due to the 
smaller sample size in the HUNT Study, where PTPN22-risk genotype frequencies both in 
LADA patients and in control subjects were similar to the frequencies observed in both our 
study and the Skåne Diabetes Register Study.  
We observed no association between the INS -23HphI variant and LADA. However, the 
role of this variant in LADA has been disputed. The UKPDS (INS risk genotype frequency: 
LADA, 69%; control subjects, 49%) and the Skåne Diabetes Register Study (LADA, 69%; 
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control subjects, 55%) have reported an association between the variant and LADA [280, 
284], whereas the Botnia Study (LADA, 47%; control subjects, 55%; [56]) and the HUNT 
Study (LADA, 56%; control subjects, 54%; [65]) report no association. This discrepancy may 
be due to differing patient recruitment. In the UKPDS Study, the LADA inclusion criterion 
for age-at-diagnosis was ≥25 years and for insulin-free time after diagnosis only 3 months, 
which might lead to inclusion of adult-onset T1D patients among the LADA patients. A 
similar classification problem might exist in the Skåne Diabetes Register Study, where no 
insulin-free period was required for the LADA patients. The relatively high frequency of INS-
risk genotypes among the LADA patients in the Skåne Diabetes Register Study may be an 
indication of T1D contamination in the LADA sample. This type of contamination would 
clearly affect the results, as we show that the frequency of the INS-risk genotype among 
young- and adult-onset T1D patients was similar. It is also possible that this discrepancy is 
due to different proportions of LADA patients with high GADA levels or a family history of 
T1D in each study, as the INS-risk genotype was somewhat increased in both the LADA 
patients with high GADA levels and those LADA patients with a family history of T1D. 
Compared with adult-onset T1D patients (>35 years), frequencies of the HLA-
DQB1*02/*0302 and *0302, the PTPN22 R620W CT/TT, and the INS -23HphI I/I genotypes 
in LADA patients were significantly lower, and frequency of the HLA-DQB1-protective 
genotypes was significantly higher. In studies comparing LADA patients and T1D patients 
diagnosed primarily <35 years, a similar difference emerged with respect to the HLA-DQB1-
protective genotypes [56, 65, 280]. However, there is a discrepancy with respect to the HLA-
risk genotypes. Hence, the HUNT Study [65] and the Botnia Study [56] agree with our 
observation, but in the Skåne Diabetes Register Study the HLA-risk genotype frequency in 
LADA patients was similar to its frequency in T1D patients diagnosed at <35 years [280]. 
This discrepancy may be ascribed to T1D contamination in the LADA sample, as already 
mentioned, or to a higher proportion of LADA patients with high GADA levels in the Skåne 
Diabetes Register Study. The latter explanation is supported by the correlation between 
GADA level and HLA-DQB1-risk genotype frequency observed in our present study and by 
others [56, 62, 65]. The HLA-DQB1*0602(3)/X or *0602(3)/*0301 protective genotypes also 
differed significantly by GADA level among LADA patients. Thus, the hypothesis of a higher 
frequency of LADA with a high GADA level in the Skåne Diabetes Register Study is further 
supported by the lower frequency of HLA-DQB1-protective genotypes in the Swedish LADA 
patients (8.1%), as compared with our LADA patients (19%). Our results clearly support a 
strong correlation between GADA level and prevalence of T1D-associated risk genotypes, as 
also the PTPN22- and CTLA4-risk genotype frequencies were higher in the LADA patients 
with high GADA levels. For PTPN22, this notion is supported by the NIRAD Study, where 
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association between the locus and LADA was only observed in patients with high GADA 
levels [282]. 
Studies on T2D-susceptibility variants in LADA are few. In our sample, only the CT/TT 
genotype of the TCF7L2 rs7903146 variant was associated with LADA in general. The 
TCF7L2 association with LADA was also reported in the Skåne Diabetes Register Study 
[280], and in a meta-analysis comprising five studies [281]. Despite reporting risk-genotype 
frequencies similar to those in the Skåne Diabetes Register Study, the HUNT Study observed 
no association [65]. Taken all together, these data support an association between the TCF7L2 
variant and LADA; the lack of association in the HUNT Study is most likely due to its 
smaller sample size.  
Based on the correlation between GADA level in the LADA patients and distribution of 
the T1D-susceptibility genotypes, we expected an inverse correlation between GADA level 
and the T2D-susceptibility genotypes. This correlation was observed for SLC30A8 R325W 
and FTO rs9939609, and the SLC30A8 variant was associated with LADA with low GADA 
levels. Supporting our results, the HUNT Study reported a similar correlation for another FTO 
variant (rs8050136), and a non-significant trend for the SLC30A8 R325W variant [65]. The 
distribution of the TCF7L2 rs7903146, KCNQ1 rs2737895, and PPARG P12A genotypes was 
independent of GADA level. For TCF7L2, this is contrary to the NIRAD Study reporting an 
association between the locus and LADA only in patients with low GADA levels [283]. It has 
also been suggested that the association between the TCF7L2 variant and LADA is stronger 
among non-overweight LADA patients [281]; this observation was not, however, supported 
by our data.   
Compared with adult-onset T1D, the frequencies of the T2D-associated TCF7L2 and 
SLC30A8 genotypes in LADA patients were significantly higher. Compared with T2D 
patients, the frequency of the FTO-risk genotype in LADA patients was lower, even when 
adjusted for BMI. In sum, with respect to the T2D-susceptibility gene variants, LADA differs 
from both adult-onset T1D and from T2D. This conclusion is further supported by data on the 
T1D-susceptibility gene variants; LADA differed from both adult-onset T1D and from T2D, 
with respect to HLA-DQB1-risk and -protective genotypes, as well as PTPN22-risk 
genotypes, and from adult-onset T1D also with respect to the INS-risk genotype. These 
genetic differences between LADA and adult-onset T1D may be a contributing factor to the 
milder reduction in beta-cell function observed in LADA. And the genetic differences 
combined with the observed clinical and immunological differences between these two 
diabetic subgroups imply that the pathophysiological process underlying LADA differs from 
the process underlying T1D. Hence, our data do not support the categorisation of LADA as an 
age-related extension of childhood T1D, but instead suggest that LADA is a slowly 
progressive form of autoimmune diabetes distinct from T1D. The distinction between LADA 
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and T1D is supported by studies showing differences between the two diabetic subgroups 
regarding GADA-epitope recognition and -IgG subclass profile [71, 301-305] as well as 
regarding cellular immune reactivity to islet proteins [306]. Furthermore, in sera from T1D 
patients, 60% of ICA staining is blocked by GADA and IA-2A, whereas only 37% is blocked 
in sera from LADA patients. These results indicate that yet-unidentified autoantibodies may 
be more prevalent in LADA than in T1D [307].  
 
3. GENETIC HETEROGENEITY IN LADA 
Clinically, those LADA patients with low GADA levels were more T2D-like, whereas those 
with high GADA levels were more T1D-like. GADA level was also associated with genetic 
differences with respect to HLA-DQB1-risk and –protective genotypes as well as risk 
genotypes in PTPN22, CTLA4, SLC30A8, and FTO. Thus, our results clearly support genetic 
and phenotypic heterogeneity within LADA attributable to the strength of GADA reactivity, 
which possibly signifies the magnitude of autoimmune destruction of pancreatic beta cells. 
The phenotypic difference between patients with high and low GADA levels may be 
clinically relevant and represent a central distinguishing factor for choosing insulin therapy or 
lifestyle-changing intervention. In the NIRAD Study, GADA levels show a bimodal 
distribution, facilitating an easy subdivision into two separate LADA subtypes [62]. In other 
LADA cohorts, including ours, the distribution of GADA levels is continuous, making it 
challenging to determine the cut-off between high and low GADA levels. 
Even a low GADA level may represent an autoimmune-disease process, where the beta-
cell function is relatively well-preserved. This notion is supported by the observation of 
significantly lower insulin secretion even in LADA patients with low GADA reactivity 
compared with T2D patients. Genetically, the LADA patients with a low GADA level and the 
T2D patients were similar. Thus, low-level GADA positivity could also result from false-
positive GADA reactivity in the assay, in which case these subjects would be T2D patients 
incorrectly diagnosed with LADA. It is impossible to eliminate this potential misclassification 
of T2D patients, as no alternative diagnostic test that shows higher specificity exists. 
Compared with adult-onset T1D patients, even LADA patients with a high GADA level 
had significantly higher levels of C-peptide and had a significantly higher frequency of both 
the TCF7L2-risk genotypes and of the HLA-DQB1-protective genotypes. These observations 
suggest that even though LADA patients with high GADA levels are more T1D-like, they are 
still phenotypically and genetically distinct from adult-onset T1D patients. 
Overall, the autoimmune attack seems to be milder, and the disease progression seems 
to be slower in LADA patients than in adult-onset T1D patients, especially in LADA patients 
with low GADA concentrations. These differences may be a reflection of LADA patients’ 
lower genetic predisposition. Family history of T1D was also associated with genetic 
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heterogeneity in LADA, which suggests that family history is a factor that should be 
considered in study of LADA genetics. 
 
4. PHENOTYPIC ASSOCIATIONS OF T1D- AND T2D-SUSCEPTIBILITY 
VARIANTS  
Although we have reported an association between family history of T1D and development of 
non-insulin dependent diabetes [54], T1D-susceptibility variants in HLA-DQB1, PTPN22, 
INS, and CTLA4 were not associated with non-insulin-dependent diabetes in the same study 
sample. Thus, these T1D-susceptibility variants do not seem to contribute to a direct genetic 
overlap between T1D and T2D. Well-powered studies of identified T1D-susceptibility 
variants in T2D and vice versa also give little support to genetic overlap between the two 
diabetic subtypes. Genetic overlap cannot, however, be excluded. Thus far, only common 
T1D- and T2D-susceptibility variants have been identified, representing only a fraction of the 
genetic heritability. It is therefore possible that yet-unidentified rare variants will contribute to 
a genetic overlap. As for the majority of the T1D- and T2D-susceptibility loci identified, 
causal variants underlying the statistical associations remain unidentified. The causal variants 
might have higher penetrance than do the proxies identified in the GWAS. Assessing the true 
causal variants would therefore increase the statistical power considerably. One speculation is 
that it is the variants associated with insulin resistance that are shared between T1D and T2D 
[308], as exemplified by PPARG [248, 270-272]. To date, only a few of the T2D-
susceptibility variants identified affect insulin resistance. These variants seem to have lower 
effect sizes than do variants associated with beta-cell function and are therefore harder to 
identify and require larger sample sizes for study. Furthermore, because the T2D-
susceptibility variants have thus far mainly been analysed in T1D children, it is possible that 
T2D-associated variants are associated with adult-onset T1D. This hypothesis is, however, not 
supported by the observance of a lack of association between adult-onset T1D and the T2D-
susceptibility variants in TCF7L2 (rs7903146) and SLC30A8 (R325W).  
The association between an increased number of T1D-susceptibility variants and 
reduced C-peptide levels in T2D patients, however, points to a possible involvement of the 
T1D-susceptibility variants in the pathogenesis of T2D. The HLA-DQB1, PTPN22, INS, and 
CTLA4 T1D-susceptibility variants - combined in a genetic risk score - were also associated 
with reduced C-peptide levels in both non-diabetic subjects and LADA patients, which 
indicates that these variants signify a reduced insulin-secretory capacity which may lead to 
development of diabetes in susceptible individuals. In non-diabetic subjects, the HLA-
DQ2.5/DQ8 and PTPN22 CT/TT genotypes were associated with the presence of GADA. 
Both associations were accentuated in subjects with a family history of T1D, and in this 
subgroup, association with GADA was also evident for the INS-risk variant. For HLA, our 
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results support the hypothesis that suggests that autoantigenic targets change over time [23, 
30, 187-190, 195]. Both in T1D patients [196, 309] and in non-diabetic subjects, GADA 
expression seems to be independent of the CT60 variant in CTLA4.  
Frequencies of the HLA-DQB1 and PTPN22-risk genotypes in LADA patients and 
among GADA-positive non-diabetic adults were similar. This similarity indicates that these 
T1D-susceptibility variants are associated with initiation of the autoimmune process leading 
to generation of autoantibodies, but additional factors are required to cause overt diabetes in 
adults. In children, the PTPN22 variant has been associated with development of persistent 
autoantibodies [310], but also, after the appearance of autoantibodies, with progression to 
T1D [311].  
Identification of the T2D-associated SLC30A8 R325W variant highlighted the important 
role of the ZnT8 zinc transporter in insulin secretion [203, 204, 237, 238]. And functional 
studies have shown that this transporter is a potential new drug target in T2D, as increased 
transporter function could potentially enhance insulin secretion [240]. Our results indicate that 
this type of drug may be effective in LADA patients as well, as the CC/CT genotypes of the 
SLC30A8 R325W variant were associated with reduced insulin secretion in these patients and 
in non-diabetic control subjects. A ZnT8-targeted drug may be especially relevant in LADA 
patients with low GADA levels, because the residual beta-cell mass in these patients seems to 
be greater than in adult-onset T1D patients and in LADA patients with high GADA levels. 
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CONCLUSIONS AND PERSPECTIVES 
 
 
 LADA shared a genetic predisposition with both T1D (HLA-DQB1, PTPN22, CTLA4) and 
T2D (TCF7L2, SLC30A8), and differed from adult-onset T1D clinically, 
immunologically, and genetically. 
 
 Genetic heterogeneity in LADA was linked to GADA reactivity (HLA-DQB1, PTPN22, 
CTLA4, and SLC30A8) and family history of T1D (HLA-DQB1 and TCF7L2). 
 
 HLA-DQ2.5/DQ8 and PTPN22 CT/TT genotypes were associated with GADA in non-
diabetic adults and carrying of an increased number of T1D-susceptibility genotypes was 
associated with reduced insulin secretion, evident in both LADA and T2D patients as well 
as in non-diabetic adults. 
 
LADA is genetically heterogeneous, and it appears to be a slowly progressive form of 
autoimmune diabetes distinct from T1D. T1D-susceptibility variants in HLA-DQB1, PTPN22, 
INS, and CTLA4 were not directly associated with development of non-insulin dependent 
diabetes, but signified a mild degree of beta-cell destruction in non-diabetic adults (reduced 
insulin secretion and GADA) as well as in LADA and T2D patients (reduced insulin 
secretion).  
Our data have added to the genetic knowledge of LADA, but the question of whether 
unique LADA-susceptibility loci exist remains unanswered. One obvious way to answer this 
question is to conduct a GWAS of LADA. This hypothesis-free approach could potentially 
reveal loci shared between LADA and T1D or T2D, and reveal novel loci exclusive to 
LADA. Such novel loci may point to molecular pathways distinguishing the LADA 
phenotype.  
A major obstacle to performing a well-powered GWAS study is, however, the 
requirement for a substantial sample of well-characterized LADA patients. One way to 
overcome this would be to combine existing LADA cohorts through international 
collaboration. This strategy would, however, require a consensus as to the unit for GADA 
measurement, as to the threshold for GADA positivity, and as to general diagnostic criteria 
for LADA. The WHO units/ml is defined in relation to a standard reference [308] and has 
been validated in international workshops [309]. This would therefore be the natural choice 
for a consensus GADA unit. Achieving a consensus on diagnostic criteria is more 
challenging, because choice of a cut-off limit for GADA reactivity, for age at onset, and for 
insulin-free period after diagnosis always will be arbitrary, and these cut-off limits may fail to 
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represent distinct clinical differences. It is almost inevitable that the characteristics of LADA 
patients will vary between studies; it will therefore also be important to seek ways to account 
for this when performing genetic analyses. Adult-onset T1D patients would also be of great 
interest to explore in a genome-wide setting to uncover the genetic cause of their slower 
autoimmune beta-cell destruction. Associated genetic loci may point to biological pathways 
underlying their delayed disease onset and hence reveal important therapeutic targets for T1D. 
Moreover, further exploration of the clinical consequences of GADA positivity and level in 
adults prior to and following development of diabetes would be of great importance to 
determine whether autoantibody status truly affects the disease course. 
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